TITLE

Using controlled interrupted time series to estimate the population-level effects of Ontario's recently implemented overdose prevention sites and consumption and treatment services

Dimitra Panagiotoglou[1], PhD; Jihoon Lim[1], MS

[1]Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada

Corresponding Author:

Dimitra Panagiotoglou
Department of Epidemiology, Biostatistics and Occupational Health
School of Population and Global Health
McGill University
2001 McGill College Avenue Suite 1200
Montreal, Quebec H3A 1G1
Email: dimitra.panagiotoglou@mcgill.ca
Telephone: +1 514 398 8451

ABSTRACT (292 / 300 words)

Background: In 2017, Ontario implemented its first supervised consumption site (SCS). We tested whether operating any SCS, was associated with opioid-related health service use or mortality rates at the provincial or public health unit (PHU) level.

Methods: We used monthly counts of all opioid-related emergency department (ED) visits, hospitalizations, and deaths between January 2014 and March 2021 as our three, independent outcomes. For each PHU that implemented any SCS, we created a synthetic control as a weighted combination of unexposed PHUs, and estimated the population-level effects using controlled interrupted time series with segmented regression. We adjusted for time-varying effects of persons dispensed prescription opioids for pain or opioid agonist treatment, naloxone kits distributed, and total booth-hours offered, correcting for seasonality and autocorrelation.

Results: During the study period, nine out of 34 PHUs began operating at least one SCS. Although we observed no level or trend effects on mortality rates, province-wide ED visits decreased 0.79 per 100,000 population (95%CI: -1.54, -0.04); and monthly ED visit (-0.15; 95%CI: -0.21, -0.08) and hospitalization (-0.02; 95%CI: -0.05, 0.00) rate trends declined faster in treated PHUs. Locally, trend differences were observed for London (-0.19, 95%CI: -0.37, -0.01), Niagara (-0.49; 95%CI: -0.82, -0.15), and Thunder Bay (-0.35, 95%CI: -0.60, -0.10) ED visits; London (-0.06, 95%CI: -0.11, -0.02), and Niagara (-0.08, 95%CI: -0.16, -0.01) hospitalizations; and Hamilton (-0.12, 95%CI: -0.17, -0.06), and Kingston (-0.05, 95%CI: -0.10, 0.00) mortality rates. For every hundred booth-hours, ED visit rates decreased in London (-2.97, 95%CI: -4.45, -1.49), Niagara (-9.70, 95%CI: -16.08, -3.31), and Ottawa (-0.26, 95%CI: -0.34, -0.17), while increasing in Guelph (2.39, 95%CI: 0.73, 4.04). Meanwhile, death rates decreased in Toronto (-0.17, 95%CI: -0.32, -0.02), Hamilton (-1.68, 95%CI: -2.87, -0.48), London (-0.45, 95%CI: -0.76, -0.14) and Niagara (-1.78, 95%CI: -2.99, -0.58), Ottawa (-0.04, 95%CI: -0.07, -0.02), and Thunder Bay (-0.55, 95%CI: -1.08, -0.03) per 100,000 population per hundred booth-hours.

Conclusion: Although SCSs alone are insufficient to stem the harms of the ongoing opioid overdose epidemic, they play a critical role in local harm reduction.

Key words: overdose prevention sites, supervised consumption sites, harm reduction interventions, interrupted time series, synthetic controls

INTRODUCTION

Canada has an opioid overdose problem. Between January 2016 and June 2021, there were 24,626 opioid overdose deaths, and at least 27,604 opioid poisoning hospitalizations (Special Advisory Committee on the Epidemic of Opioid Overdoses, 2022). Although British Columbia is Canada's hardest hit province, Ontario is a close second in disease burden and health service use. Over a ten-year period (2007-2016, inclusive), Ontario's emergency department (ED) visits increased 50% to 55.3 per 100,000 population (Tam, 2018) and hospitalizations rose 12% to 14.8 per 100,000 population (Canadian Institute for Health Information, 2018). For the first time in decades, male life expectancy at birth decreased as a consequence of high opioid-related mortality observed in younger adults (25 – 44 years of age) (Statistics Canada, 2020).

Overdose prevention sites (OPS) and consumption and treatment services (CTS) are among a suite of harm reduction interventions (e.g., supervised injection facilities, needle and syringe programs, naloxone distribution programs, drug checking services, and opioid agonist treatment (OAT)) increasingly offered across Canada to mitigate the negative physical and social consequences of illicit drug use (Strike & Watson, 2019). Historically unsanctioned, OPSs are nimble, grass-roots, peer-managed responses to the neglected needs of people who use illicit substances. Aside from providing critical overdose reversal services, they offer overdose prevention education, Take Home Naloxone training and distribution, access to drug use equipment, and safe disposal of used equipment (BC Ministry of Health, 2017). As a peer-led intervention, OPSs do not require the presence of professional medical staff (e.g. nurses) but are also unable to provide the wrap around health and social services found at CTSs.

In 2017, the federal government lifted exemption requirements under section 56.1 of Canada's Controlled Drugs and Substances Act to allow communities to implement OPSs legally during the ongoing overdose emergency. Supervised consumption sites, better known as CTSs in Ontario and safe injection facilities in British Columbia, continued to require Health Canada approval – although the process was streamlined.

While evidence demonstrates supervised consumption sites (namely, safe injection facilities) reduce mortality and health service use, they remain politically controversial (Potier C, Laprévote V, Dubois-Arber F, Cottencin O, & Rolland B, 2014). Much of the available evidence is from the concentrated drug use epidemics of Vancouver's Downtown Eastside and Sydney's 'red light' district and specific to injection drug use (Kennedy, Hayashi, Milloy, Wood, & Kerr, 2019; Potier C et al., 2014). The effects of supervised consumption site variants such as OPSs and CTSs (herein collectively called SCS) remain unclear, particularly in contexts where the population is geographically diffuse, services are not restricted to people who inject drugs, and mobile rather than fixed sites operate. Further, most studies fail to distinguish the effects of supervised consumption sites from other harm reduction interventions also

available (Caulkins, Pardo, & Kilmer, 2019). Our aim is to estimate the population-level effects of Ontario's SCSs implemented between 2017 and 2020 (inclusive) on opioid-related ED visit, hospitalization, and mortality rates, while controlling for other time-varying interventions including residents treated with prescription opioids, residents receiving OAT, and number of pharmacy and community naloxone kits distributed, all per 100,000 population. We hypothesize that SCSs had no level and modest trend effects on health service use and mortality rates based on results from a similar analysis we conducted using the British Columbia Centre for Disease Control's Overdose Cohort data (Panagiotoglou, 2022).

METHODS

Study Design

We conducted a retrospective, cohort study to compare changes in opioid-related ED visit, hospitalization, and mortality rates between Ontario public health units (PHU) that implemented any SCS and those that did not.

Setting

Ontario is Canada's most populous province with approximately 14.75 million residents (Government of Ontario, 2020), 97% of whom are covered by the provincial health insurance program (Izenberg, Iroanyah, & Thompson, 2018). Within the province, health promotion and disease prevention are administered by PHUs, which are mutually exclusive and exhaustive health boundaries. The 34 PHUs range from 33,166 residents in Timiskaming, the province's most sparsely populated health unit, to 3,094,237 for its densest, most populated urban unit, Toronto (Government of Ontario, 2020).

Beginning in 2016, several provincial and federal harm reduction interventions were implemented to stem the rising rate of opioid-related overdose deaths. In June 2016, the Ontario Naloxone Program for Pharmacies (ONPP) began offering naloxone injection kits at no charge to individuals at risk of opioid-related overdose or persons in a position to assist someone at risk of an overdose, while select community-based organizations continued to dispense naloxone to at-risk clients, friends and family through a program that first began in 2013 (Canadian Centre on Substance Abuse & Canadian Community Epidemiology Network on Drug Use, 2016; Canadian Pharmacists Association, 2017). Shortly thereafter, naloxone kits transitioned from an injectable formulation to nasal spray (January 2017), the federal government's Good Samaritan Drug Overdose Act became law (May 2017) (Government of Canada, 2018), and PHUs began sub-distributing naloxone kits to community-based organizations much more widely through the Ontario Naloxone Program (ONP, September 2017) (Gogolishvili & Wasdell, 2020). Meanwhile, Health Canada issued an exemption to Ontario to establish

legally sanctioned temporary OPSs on December 7, 2017, although some cities had begun operating unsanctioned sites earlier in the year (Ontario Ministry of Health & Ontario Ministry of Long-Term Care, 2018). Beginning October 2018, the government of Ontario enforced a list of required services and metrics that needed to be met for continued approval and financial support of SCSs (Ministry of Health and Long-Term Care, 2018) and applied a cap to the number of sites allowed, ostensibly restricting provision of sites to larger cities (Russell, Imtiaz, Ali, Elton-Marshall, & Rehm, 2020).

Between June 2017 and December 2020, nine of the 34 provincial PHUs began operating at least one SCSs. These were in Toronto (n=9, 2 additional shelter-hotel sites), Ottawa (n=5), and one each in Hamilton, Kingston, London, Niagara, Thunder Bay, Guelph, and Waterloo (Pivot Legal Society, 2020) (Supplementary Table 1 for implementation dates, hours of operation, and capacity).

Data collection and measures

We used monthly counts of all opioid-related ED visits, acute care hospitalizations, and deaths between January 2014 and March 2021, reported at the PHU-level in Ontario's publicly accessible Interactive Opioid Tool (Ontario Agency for Health Protection and Promotion (Public Health Ontario), 2020).

Opioid overdose related emergency department visits, acute care hospitalizations, and deaths:

The Interactive Opioid Tool includes all opioid-related ED visits and acute care hospitalizations as captured in the province-wide National Ambulatory Care Reporting System (NACRS) and Discharge Abstract Database (DAD), respectively. All fatal events where accidental opioid poisoning from codeine, fentanyl (including carfentanil and other fentanyl analogues), heroin, hydrocodone, hydromorphone, methadone, morphine, or oxycodone was considered a contributing cause of death according to the Office of the Chief Coroner are also included. More than one opioid can be present at time of death, and presence of a drug does not necessarily indicate that it contributed to death.

We converted event counts to rates per 100,000 to enable comparability between PHUs using the Ontario Ministry of Health and Long-Term Care's IntelliHealth population level estimates (2003-2016) and population projections (2017 – 2021) also available in the Interactive Opioid Tool.

We supplemented the PHU-level overdose event data with population-level annual demographics (percent of the population without a high school diploma, immigrant, and visible minority; median household income); age- and sex-standardized rates of alcohol-related emergency department visits and hospitalizations; and monthly counts of concomitant interventions: persons receiving opioid prescriptions (for pain and OAT, separately), naloxone kits distributed. We also added a measure of SCS intervention 'intensity' in the form of booth-hours as the sum of the product of individual spaces and hours available

for supervised consumption of illicit substances per site and PHU. For full definitions, data sources, and methods, please see supplementary material.

Ethics approval

This study was exempt from ethics review by McGill University's Institutional Review Board.

Statistical analysis

We used controlled interrupted time series with segmented regression to test whether PHUs that implemented any SCS observed improvements in opioid-related ED visit, hospitalization, or mortality rates compared with PHUs that did not. Treated groups included all PHUs that implemented at least one SCS during the study period. Synthetic controls were derived for each treated PHU per outcome from a donor pool of non-treated PHUs using Abadie et al.'s data-driven method and the Synth package with its extensions in R (Abadie, Diamond, & Hainmueller, 2011; Castanho Silva & DeWitt, 2020; Degli Esposti et al., 2020). The pre-intervention period was restricted to three years to optimize prediction of the treatment group by the comparison group (Bilinski, 2021).

We fitted the following linear regression model for intervention status *j*, for group *k*, at time *t*:

$$\begin{aligned}\mathrm{Outcome}_{jkt} = {} & \beta_0 + \beta_1 \mathrm{time}_t + \beta_2 \mathrm{group}_k + \beta_3 \mathrm{time}_t \mathrm{group}_k + \beta_4 \mathrm{level}_{jt} + \beta_5 \mathrm{trend}_{jt} + \beta_6 \mathrm{level}_{jt} \mathrm{group}_k \\ & + \beta_7 \mathrm{trend}_{jt} \mathrm{group}_k + \beta_8 \mathrm{booth_hours}_{jkt} \\ & + \beta_9 \mathrm{RxOpioids}_{jkt} + \beta_{10} \mathrm{OAT}_{jkt} + \beta_{10} \mathrm{naloxone}_{jkt} + \varepsilon_{jkt}\end{aligned}$$

Where β_0 is the intercept for the control; β_1 represents the pre-intervention linear trend for the control; β_2 indicates the pre-intervention level difference between the treated and control intercepts; β_3 captures the pre-intervention trend difference between the treated and control groups; β_4 represents the level change in the control post-intervention; β_5 indicates the change in trend for the control post-intervention; β_6 captures the level change in the treated group *relative* to the control group's level post-intervention; β_7 indicates the trend difference for the treated group *relative* to the control group's trend post-intervention; and β_8 represents the intensity of the intervention using total booth-hours available per 100,000 population in the treated group. We also adjusted for other relevant time-varying confounders following the disjunctive cause criterion for confounder selection such that all covariates are known or potential causes of the exposure (i.e., SCS implementation) and/or the outcome (i.e., opioid-related ED visits, hospitalizations or death) (VanderWeele & Shpitser, 2011). Here, we adjusted for the number of residents dispensed prescription opioids for pain management (β_9), residents dispensed OAT for opioid use disorder (β_{10}), and naloxone kits dispensed (β_{11}) per 100,000 population. We also adjusted for

seasonality using harmonic terms, and used Newey-West standard errors to correct for autocorrelation as identified using plots of residuals.

Since the initial SCS was implemented at different times across the nine PHUs, we applied a multiple baseline approach (i.e. using intervention time instead of calendar time) to measure the overall effect of any SCS on population-level ED visit, hospitalization, and mortality rates across the province and report results for individual treated/synthetic control pairs in supplementary tables.

We assessed the significance of the effect of SCS implementation locally using the root mean square prediction error (RMSPE) ratio and the placebo test – a non-parametric permutation test. For sensitivity analysis, we tested the effects of the Good Samaritan Drug Overdose Act(Government of Canada, 2018) across all treated/synthetic control pairs (not shown here), and terminated the observation period before March 2020 and the onset of COVID-19 related service restrictions and border closures.

All analyses were conducted using R version 4.0.5(R Core Team, 2014). All data used for this analysis are publicly available through the Ontario Opioid Tool, Ontario Drug Policy Research Network, news articles and SCS hours of operation.

RESULTS

We excluded two PHUs that merged during the study period (Southwestern and Huron-Perth) with a combined population of approximately 336,000 (2.3%) from subsequent analysis owing to the incomplete demographic data available and differences between public health units' and Statistics Canada's jurisdictional boundaries. For the remaining 32 PHUs, there were 53,806 ED visits, 13,734 hospitalizations and 9,377 mortalities for opioid-related overdose events between January 2014 and March 2021.

When the first unsanctioned OPSs began operating in Toronto and Ottawa, Hamilton (n=9, 1.58 per 100,000), Niagara Region (n=7, 1.53 per 100,000), Toronto (n=27, 0.92 per 100,000), Peel (n=11, 0.73 per 100,000), Ottawa (n=7, 0.70 per 100,000), and York (n=7, 0.59 per 100,000) reported the highest opioid-related mortality counts; while Kingston-Frontenac-Lennox-Addison (n=5, 2.42 per 100,000), North Bay-Parry Sound (n=3, 2.34 per 100,000), Peterborough (n=3, 2.11 per 100,000), Thunder Bay (n=3, 1.95 per 100,000), and Haldimand-Norfolk (n=2, 1.79 per 100,000) had the highest mortality rates. Meanwhile, small, less urban PHUs (Chatham-Kent, Eastern Ontario, Haliburton-Kawartha-Pine Ridge, Hastings-Prince Edward, Leeds-Grenville, Porcupine, Renfrew, Timiskaming, and Wellington-Dufferin-Guelph) reported no mortality events. These patterns persisted for ED and hospitalization events such that the largest, most urban PHUs did not have the highest event rates despite high event counts. Overall, treated and potential control units in the donor pool were sufficiently similar in population demographics

and outcomes (i.e. none of the treated units were outside the convex hull of the donor pool), overdose risks and relevant policies; with no known external shocks specific to control units (Bouttell, Craig, Lewsey, Robinson, & Popham, 2018).

Tables 1 and 2 show the predictor weights and public health units used to create the synthetic controls per treated unit by outcome.

Table 1. Synthetic control predictor weights [here]

ED=Emergency department; Hosp=Hospitalization; OAT=Opioid agonist treatment; pop=population

Table 2. Synthetic control donor public health units [here]

Table 3 shows the balance between treated and synthetic controls' predictors compared with the overall sample means at time of intervention implementation, per outcome. Notably, perfect balance is not observed across all predictors for each treated-synthetic control unit given the weight of each predictor per outcome ranged from 0.00 (no effect in creating synthetic control for that outcome) to 0.86 for proportion unemployed when creating London's synthetic control for mortality rates (treated: 7.53, synthetic control: 7.53, sample mean: 7.89).

Table 3. Characteristics of treated units, synthetic controls (per outcome) and overall sample mean at time of intervention [here]

ED=Emergency department; Hosp.=Hospitalizations; pop.=population; prop.=proportion; w/o=without

Although there is no consensus on a RMSPE threshold distinguishing well-matched from inadequately constructed synthetic controls, using the RMSPE and outputs from the adjusted segmented regression (β_3), we found the monthly pre-intervention outcome trends were parallel for most treated / synthetic control unit pairs (Table 4, Supplementary Table 3). From our adjusted models, modest differences in pre-intervention trends between treated and synthetic control pairs were observed between Kingston and its synthetic control for ED visit rates (0.12, 95% CI: 0.00, 0.25); Waterloo's (-0.02, 95% CI: -0.04, 0.00) and Niagara's (0.03, 95% CI: 0.00, 0.06) hospitalization rates compared with their respective controls; and Thunder Bay's mortality rate (0.04, 95% CI: 0.00, 0.09) relative to its control, only. Results from our multiple baseline analysis found small but significant differences in pre-intervention trends for ED visit (0.02, 95% CI 0.01, 0.04) and mortality (0.01, 95%CI: 0.00, 0.01) rates.

The results from the multiple baseline segmented regressions on the effects of SCSs across the province found significant differences in aggregate post-intervention ED visit rate level (-0.79, 95% CI: -1.54, -0.04) and monthly trend (-0.15, 95% CI: -0.21, -0.08) per 100,000 population; and monthly trend for hospitalization rate (-0.02, 95% CI: -0.05, 0.00). No change in mortality rate level (-0.17, 95% CI: -0.38, 0.04) or trend (-0.01, 95% CI: -0.03, 0.01) post-SCS implementation (Table 4, Figure 1) was observed. Notably, for every hundred persons on OAT, there were 9.05 (95% CI: -14.16, -3.94) fewer ED visits per 100,000 population and 3.35 (95% CI: -4.89, -1.81) fewer deaths per 100,000 population. For every hundred naloxone kits dispensed, there were 0.38 (95% CI: -0.67, -0.08) fewer deaths per 100,000 population.

Table 4. Crude and adjusted segmented regression output for treated/synthetic control aggregate analysis [here]

*Adj. = Adjusted with robust standard errors generated using Newey-West method

Figure 1. Controlled interrupted time series plots of aggregate analyses [here]

ED visits

ED visits per 100,000 population increased in Toronto (1.58, 95% CI: 0.04, 3.12), London (5.34, 95% CI: 1.61, 9.08), and Niagara (25.88, 95% CI: 6.44, 45.33) post-implementation relative to their respective controls. Aside from these level increases, trend differences were observed in London (-0.19, 95% CI: -0.37, -0.01), Niagara (-0.49; 95% CI: -0.82, -0.15), and Thunder Bay (-0.35, 95% CI: -0.60, -0.10) where monthly rates of ED visits declined faster for these treated units than their synthetic controls. For every hundred booth-hours offered, ED visit rates decreased in Toronto (-0.17, 95% CI: -0.32, -0.02), London (-2.97, 95% CI: -4.45, -1.49), Ottawa (-0.26, 95% CI: -0.34, -0.17) and Niagara (-9.97, 95% CI: -16.08, -3.31); but increased in Guelph (2.39, 95% CI: 0.73, 4.04). For every hundred persons on prescription opioids for pain management, Kingston's ED visits increased 0.62 per 100,000 population (95% CI: 0.12, 1.11) compared with its control; while ED visits in Thunder Bay increased 0.8 per 100,000 population (95% CI: 0.05, 1.66) with every hundred naloxone kits dispensed.

Hospitalizations

Hospitalizations per 100,000 population increased in London (1.06, 95% CI: 0.18, 1.95), and Waterloo (0.73, 95% CI: 0.05, 1.54) immediately following implementation of any SCS. Compared with their controls, hospitalization rate trends declined more rapidly in London (-0.06, 95% CI: -0.11, -0.02) and Niagara (-0.08, 95% CI: -0.16, -0.01). For every hundred persons on prescription opioids for pain

management, hospitalizations increased in Kingston (0.16, 95% CI: 0.00, 0.32). Meanwhile, for every hundred naloxone kits dispensed, hospitalization rates decreased in London (-0.34, 95% CI: -0.56, -0.12), but increased in Waterloo (0.18, 95% CI: 0.00, 0.45).

Deaths

Hamilton (2.98, 95% CI: 0.79, 5.16) and Niagara (4.67, 95% CI: 0.99, 8.35) observed positive changes in mortality rates per 100,000 population immediately following the operation of their SCS. Mortality rates declined more rapidly in Hamilton (-0.12, 95% CI: -0.17, -0.06) and Kingston (-0.05, 95% CI: -0.10, 0.00) compared with their synthetic controls. Per hundred booth-hours offered, mortality rates decreased in Toronto (-0.17, 95% CI: -0.32, -0.02), Hamilton (-1.68, 95% CI: -2.97, -0.48), London (-0.45, 95% CI: -0.76, -0.14), Ottawa (-0.04, 95% CI: -0.07, -0.02), Niagara (-1.78, 95% CI: -2.99, -0.58) and Thunder Bay (-0.55, 95%CI: -1.08, -0.30). For every hundred naloxone kits dispensed, Toronto observed 0.34 fewer deaths (95% CI: -0.61 -0.08) per 100,000 population. Meanwhile, London observed 1.28 fewer deaths (95% CI: -2.49, -0.07) per 100,000 population for every hundred persons on OAT.

Sensitivity analysis found these effects persisted, with outcome effects larger in the period between implementation and March 2020 (Supplementary Figures 1 – 3).

DISCUSSION

Our province-wide analysis found positive effects of SCSs on opioid-related ED visits and hospitalizations, but no statistically significant effect on opioid-related mortalities. These results agree with our province-wide findings on the effects of OPSs in British Columbia, while demonstrating beneficial impacts on hospitalizations not observed when we analyzed the BC Centre for Disease Control's Overdose Cohort (Panagiotoglou, 2022). The Ontario results also align with findings from a mathematical model estimating the synergistic effects of BC's harm reduction interventions (Irvine et al., 2019).

Extensive research on variations of SCSs has yet to show consistent population-level benefits. Past studies demonstrated Vancouver's supervised injection facility, first implemented in 2003, significantly reduced local overdose mortality rates (Marshall BDL, Milloy MJ, Wood E, Montaner JS, & Kerr T, 2011). More recent studies evaluating other SCSs have found consistently positive effects on overdose-related ED visit and paramedic attendance rates, but no evidence of effect on mortality or hospitalization rates (NCHECR, 2007; Panagiotoglou, 2022; The Evaluation of Overdose Prevention Sites Working Group & Lori Wagar, 2018). By comparing outcome rates between PHUs that implemented any SCS with comparable synthetic PHUs not exposed to the intervention, controlling for concomitant time-varying

interventions (i.e. naloxone kits distributed, persons receiving OAT and opioid medication for pain management) as well as changes in intervention scale (booth-hours), conducting extensive sensitivity analysis, and pooling the analysis using a multiple baseline approach – ours is the first rigorous, province-wide study on the effects of SCSs on a population outside British Columbia. Our results suggest that the effects of SCSs are context specific, and a combination of harm reduction interventions best addresses the opioid overdose epidemic.

Possible explanations for findings

The observed level increase in ED visit rates following implementation may be a consequence of SCS operating guidelines. The same phenomenon was observed in our BC study where OPS guidelines developed by the BC Centre on Substance Use and The Portland Hotel Society initially recommended calling emergency health services and transferring care to paramedics for all overdose events reversed with naloxone (BC Centre on Substance Use, 2017).

The positive effects of SCSs on opioid-related ED visits and hospitalizations but not on mortality may be a consequence of access barriers first described elsewhere. Work examining successful implementation and uptake of OPSs in British Columbia found persisting stigma and police presence reduced their social acceptability and use by at-risk populations (Collins et al., 2019). Meanwhile, hours of operation, facility capacity, and absence of safe inhalation rooms limited their effectiveness (The Evaluation of Overdose Prevention Sites Working Group & Lori Wagar, 2018). Similar barriers have been described in qualitative work on Ontario's OPSs (Foreman-Mackey, Bayoumi, Miskovic, Kolla, & Strike, 2019) and explain some of the design features of CTSs (e.g. permitting inhalation and other forms of drug consumption). Despite concerns that harm reduction interventions may encourage risky behaviour (Hedlund, 2000), a study examining the prevalence of unintentional overdose in a longitudinal cohort of PWID in Toronto has found no evidence of risk compensation (Scheim et al., 2021).

Strengths and limitations

Our study had some limitations. We used reported hours of operation gleaned from SCS websites, online platforms (i.e. Facebook and Twitter) or reported by local media to estimate booth-hours provided per month. Where information was missing, we assumed the number of booths matched the number included in public reports or plans prior to opening. Despite exhaustive searches, we were unable to confirm the number of booth-hours provided at Toronto's The Works' two recently implemented hotel-based resident sites, and for Ottawa's mobile site, and did not include these sites into our monthly booth-hour estimates. For COVID-19 related changes to services, if no explicit update on the number of booths was available, we assumed the number was adjusted to meet public health guidelines (e.g. where three booths normally

operated side-by-side, we assumed the middle booth was temporarily unavailable until guidelines were revised) (Public Health Ontario, 2020). These assumptions and exclusions may underestimate the number of booth-hours per PHU and overestimate the marginal effect of each additional booth-hour. However, they do not detract from the overall observed effect that booth-hours improved ED visit and mortality rates across several PHUs including in Toronto, Hamilton, London, Ottawa, Niagara and Thunder Bay. At peak service provision, SCSs in these PHUs were averting four to eighteen deaths per month.

With respect to naloxone kits distributed by community-based organizations (separate from those dispensed by participating pharmacies), we used annual reports to estimate monthly counts whenever more granular data were not available (e.g. distribution campaign or blitz for a specific period). Again, this likely introduced error to the month-to-month number of kits distributed but should have minimal effect on the overall impact of naloxone kits readily available for private use.

While we cannot definitively rule out that travel from control to treated PHUs did not dilute observed treatment effects, using maps to confirm SCS are well within PHU boundaries and assuming distance-decay effects described in other studies (Marshall BDL et al., 2011; The Evaluation of Overdose Prevention Sites Working Group & Lori Wagar, 2018) apply here, it is unlikely that population mobility across boundaries explains the effect sizes observed. This lack of evidence of spillover effects satisfies a critical assumption of synthetic control methods (Bouttell et al., 2018).

The response to the global SARS-COV-2 pandemic introduced some challenges for our analysis, including delays in public reporting of outcome data by Ontario Public Health and public health units (e.g. naloxone kits distributed). However, we were still able to observe at least fourteen months (and over three years for early adopters Toronto and Ottawa) of intervention effect post-implementation after allowing for a three month intervention ramp up period as recommended by others (The Evaluation of Overdose Prevention Sites Working Group & Lori Wagar, 2018). Further, by including periods after federal/provincial COVID-19 emergency orders were implemented in March 2020, we were able to test the effects of SCSs following a ramp-up period, other policies (e.g. Good Samaritan Drug Overdose Act), and dramatic changes in capacity (i.e. booth-hours) within distinct populations (Box, Jenkins, & Reinsel, 2011). Although we were able to adjust for reduced service capacity and changes in naloxone distribution, and OAT and prescription opioids for pain management dispensing as a consequence of social distancing measures, we were unable to directly adjust for changes in toxicity of the illicit drug supply following border closures. Potential increases in drug toxicity along with temporary reductions in booth-hours may explain the spikes in ED and mortality rates observed immediately after March 2020 (Supplementary Figures 1 and 3, respectively) (Beard et al., 2019).

CONCLUSION

Supervised consumption services are among a set of harm reduction interventions increasingly implemented across Canada to stem the ongoing opioid overdose epidemic. Our study found positive effects on ED visit and hospitalization rates across Ontario, and local improvements across all three outcomes. Although SCSs do not appear sufficient to address the ongoing epidemic on their own, they are an effective option, particularly in conjunction with OAT and Take Home Naloxone programs. Alternative interventions, including safer supply, should be rigorously explored in tandem with these harm reduction interventions. These findings are pertinent to other communities with population demographics and need distributions different from Vancouver's well studied Downtown Eastside.

ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths
0.28	0.01	0.12	0.02	0.02	0.09	0.03	0.05	0.28	0.02	0.15				
	0.01	0.22	0.03		0.21		0.01	0.39	0.31	0.01			0.18	
0.27	0.14	0.11	0.03					0.01	0.11	0.06		0.21	0.01	0.11
0.02	0.01	0.03	0.29	0.25	0.03		0.01		0.01	0.05	0.01		0.33	0.59
0.09	0.10	0.03			0.28	0.03	0.91		0.20	0.32	0.02	0.06	0.06	0.05
		0.03	0.05	0.46	0.14			0.18	0.06	0.22	0.09	0.22	0.23	
0.19		0.07	0.35		0.04	0.93				0.05	0.86	0.28	0.18	0.23
0.11	0.55	0.34	0.21	0.20	0.22					0.09	0.01	0.23	0.02	
0.04	0.18	0.05	0.03	0.07			0.01	0.13	0.29	0.05				0.02
Ottawa			**Thunder Bay**			**Guelph**			**Waterloo**					
0.53	0.32	0.69	0.82	0.51		0.02	0.30	0.43	0.02	0.21				
0.02		0.02	0.01			0.39	0.07	0.12	0.24		0.02			
0.05	0.03	0.11					0.01		0.01		0.01			
0.02	0.13	0.07				0.14	0.17		0.02	0.20				
	0.05						0.01	0.01	0.39	0.34	0.35			
0.27			0.01		0.05	0.31	0.32	0.02	0.16	0.05	0.35			
0.08	0.43	0.10	0.01		0.72			0.03	0.04		0.16			
0.02		0.02	0.01	0.32	0.20	0.01	0.06	0.40	0.12	0.20	0.11			
	0.04		0.13	0.17	0.03	0.13	0.06							

Hamilton			Kingston			London			Niagara			Ottawa			Thunder Bay			Guelph			Waterloo		
Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths	ED	Hosp	Deaths
.07		0.12					0.10		0.01			0.01												
	0.18	0.04	0.22	0.25	0.14	0.08				0.15	0.14	0.31				0.20	0.03	0.35			0.27	0.19		0.22
		0.07						0.20	0.24		0.06	0.03												
												0.01		0.15										
		0.01						0.16				0.01		0.08					0.20	0.21			0.17	
	0.09	0.02				0.19				0.02		0.01							0.01	0.10	0.23	0.29		0.39
	0.15	0.02	0.12									0.01							0.07	0.06				
		0.01										0.01					0.05							
				0.23								0.01		0.25	0.05				0.36	0.37	0.07	0.24		0.26
		0.02								0.13	0.11	0.01					0.01							
		0.01						0.21	0.01		0.01	0.05												
.14		0.01		0.01	0.14			0.20	0.37	0.01		0.01												
		0.23										0.04				0.30	0.26							
	0.03	0.02	0.05		0.04	0.24	0.26							0.07	0.02	0.13	0.30	0.33	0.04	0.05				
.49	0.03	0.26				0.04	0.18	0.13	0.01			0.04	0.35	0.18	0.28								0.46	
	0.13	0.08	0.28	0.27	0.32	0.09	0.11	0.11	0.14	0.60	0.49	0.34					0.07	0.07					0.08	
		0.01										0.01												
		0.01									0.10	0.01												
.29	0.4	0.01				0.35						0.01	0.27		0.20				0.30	0.02	0.06	0.04		0.03
		0.02	0.33	0.20	0.24		0.35					0.04				0.37	0.15	0.24		0.11		0.24	0.19	0.09
		0.01										0.01					0.05							
		0.01							0.21	0.07	0.06	0.05					0.06							
					0.12							0.01	0.38	0.29	0.44					0.07	0.38			
4	7	20	5	5	6	6	5	6	7	6	7	22	3	6	5	4	9	4	6	8	5	5	4	5

Treated	ED	Hosp.	Mortality	Sample Mean	Treated	ED	Hosp.	Mortality	Sample Mean	Treated	ED	Hosp.	Mortality	Sam Me
		Toronto					Hamilton					Kingston		
1988.06	2705.77	2094.97	2945.22	4042.24	3973.5	3957.45	3973.01	4253.87	3975.78	3709.55	3728.91	3821.3	3792.72	39
202.56	358.24	189.86	276.34	469.88	438.8	529.97	528.1	741.07	499.51	474.13	598.24	620.65	568.67	5
14.03	9.63	3.55	9.47	9.91	57.7	45.18	35.74	49.48	33.29	51.26	44.59	47.62	50.62	
192.1	264.64	224.52	327.24	278.39	242.63	383.24	435.01	266.38	286.89	270	278.11	270.26	333.53	2
720.17	1166.02	366.07	455.65	656.51	650.07	644.12	650.09	842.54	709.35	699.3	599.73	765	1502.99	7
65829	81680.06	89554.02	78670.02	70907.09	70395	72719	70407.14	69260.14	72252.29	71501	76967.9	72370.51	72091.7	722
8.2	8.04	7.64	7.87	7.78	7.07	7.1	8.67	7.92	7.89	7.3	7.3	7.8	7.82	

thetic controls (per outcome) and overall sample mean at time of intervention

London					Niagara					Ottawa				
3494.8	3820.79	7.7	4267.37	4007.65	4406.12	4216.19	4221.32	4113.73	3909.14	2176.7	2328.32	2302.66	2239.33	404
555.09	677.52	18.58	473.19	488.46	677.75	677.14	651.34	677.29	515.11	159.14	214.19	220.48	209.25	46
34.83	30.54	11.69	22.39	21.03	67	71.62	67.01	72.5	54.49	20.07	6.17	4.77	5.57	
194.9	235.03	7.7	225.29	286.89	335.2	338.2	333.64	335.26	286.89	131.03	285.84	209.72	263.03	27
490.2	1649.07	18.58	508.09	709.35	616.8	672	629.42	616.82	709.35	518.4	364.74	560.33	431.65	65
65733	71766.75	11.69	66693.31	72252.29	66145	66350.11	66288.68	68917.37	72252.29	85981	86921.7	90908.18	88739.29	7090
7.53	9.27	7.7	7.53	7.89	7.53	7.55	7.54	7.53	7.89	7.2	7.19	7.12	7.1	
16.4	21.24	18.58	18.79	19.83	17.7	17.77	18.17	18.53	19.83	12.23	17.25	16.59	17.06	2
17.5	13.97	11.69	7.18	10.74	9.13	5.94	5.69	9	10.74	26.3	42.27	35.73	41.88	1

Thunder Bay					Guelph					Waterloo				
4518.94	4511.62	4508.31	4041.91	3918.64	2913.59	3131.53	3016.32	2966.2	3982.07	2549.12	3400.1	2598.23	3296.73	375
1675.32	832.62	818.97	857.38	512.59	234.04	325.69	327.11	333.88	496.64	271.92	474.63	372.07	398.95	5
117.83	86.6	76.21	81.77	50.78	25.72	25.66	22.13	22.29	29.59	155.08	148.04	89.48	130.61	10
182.9	418.71	397.1	222.38	286.89	90.13	312.91	208.75	238.84	286.89	230.7	224.72	229.69	229.11	29
2813.03	1183.22	1805.72	1911.59	709.35	595.63	598.98	638.04	418.04	709.35	450.53	546.04	481.57	515.34	75
68755.67	67729.47	66609.55	69519.42	72252.29	84639.67	84506	84494.94	82376.85	72252.29	80131.67	79666.02	81344.53	79978.52	7359
8.4	8.83	9.27	8.4	7.89	5.5	6.83	6.9	6.34	7.89	6.47	6.9	8.12	6.5	
22.4	21.21	22.42	22.41	19.83	17.93	17.31	17.54	17.95	19.83	17.73	17.77	17.78	17.64	1
3.6	3.72	3.72	4.58	10.74	11.9	12.78	15.06	23.77	10.74	20	10.02	35.62	10.68	

pop.=population; prop.=proportion; w/o=without

Emergency department visits				Hospitalizations				Deaths			
Crude (95% CI)	P-value	Adj. (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value
0.08 (0.06, 0.09)	<0.0001	0.18 (0.09, 0.26)	0.0001	0.00 (0.00, 0.00)	0.0190	0.02 (0.00, 0.04)	0.0830	0.01 (0.00, 0.01)	<0.0001	0.06 (0.03, 0.08)	<0.0001
1.63 (1.21, 2.06)	<0.0001	3.01 (1.81, 4.20)	<0.0001	0.33 (0.22, 0.44)	<0.0001	1.22 (-0.37, 2.82)	0.1332	0.33 (0.23, 0.44)	<0.0001	1.45 (0.91, 1.99)	<0.0001
0.05 (0.03, 0.07)	<0.0001	0.02 (0.01, 0.04)	0.0101	0.00 (0.00, 0.01)	0.1387	0.01 (0.00, 0.02)	0.1106	0.01 (0.00, 0.01)	0.0015	0.01 (0.00, 0.01)	0.0090
0.59 (0.03, 1.15)	0.0395	0.08 (-0.41, 0.57)	0.7569	-0.06 (-0.21, 0.09)	0.4142	-0.09 (-0.25, 0.07)	0.2649	0.09 (-0.05, 0.23)	0.2032	0.01 (-0.13, 0.14)	0.9375
0.04 (-0.09, 0.01)	0.0857	-0.15 (-0.22, -0.09)	<0.0001	-0.01 (-0.02, 0.00)	0.2137	-0.02 (-0.03, 0.00)	0.0621	0.00 (-0.01, 0.02)	0.6299	-0.03 (-0.05, -0.01)	0.0013
0.33 (-1.12, 0.46)	0.4041	-0.79 (-1.54, -0.04)	0.0400	0.05 (-0.16, 0.26)	0.6173	0.03 (-0.22, 0.27)	0.8392	-0.10 (-0.30, 0.10)	0.3205	-0.17 (-0.38, 0.04)	0.1143
0.07 (-0.14, 0.00)	0.0517	-0.15 (-0.21, -0.08)	<0.0001	-0.02 (-0.03, 0.00)	0.0685	-0.02 (-0.05, 0.00)	0.0269	-0.01 (-0.02, 0.01)	0.3967	-0.01 (-0.03, 0.01)	0.4378
		0.19 (-0.02, 0.40)	0.0760			0.02 (-0.05, 0.08)	0.6638			0.05 (-0.01, 0.11)	0.0780
		0.04 (-0.19, 0.27)	0.7469			0.05 (-0.03, 0.13)	0.2058			0.03 (-0.03, 0.10)	0.3187
		-9.05 (-14.16, -3.94)	0.0005			-1.21 (-3.00, 0.58)	0.1861			-3.35 (-4.89, -1.81)	<0.0001
		0.73 (-0.31, 1.76)	0.1694			-0.05 (-0.39, 0.30)	0.7848			-0.38 (-0.67, -0.08)	0.0119

d using Newey-West method

REFERENCES

Abadie, A., Diamond, A., & Hainmueller, J. (2011). Synth: An {R} Package for Synthetic Control Methods in Comparative Case Studies. *Journal of Statistical Software, 42*(13), 1-17.

BC Centre on Substance Use, B. M. o. H. (2017). Supervised Consumption Services: operational guidance. In.

BC Ministry of Health. (2017). Overdose Prevention. Retrieved from https://www2.gov.bc.ca/gov/content/overdose/what-you-need-to-know/overdose-prevention

Beard, E., Marsden, J., Brown, J., Tombor, I., Stapleton, J., Michie, S., & West, R. (2019). Understanding and using time series analyses in addiction research. *Addiction, 114*(10), 1866-1884. doi:10.1111/add.14643

Bilinski, A. (2021). *Goldilocks and the Pre-Intervention Time Series: How Long is 'Just Right' and the Parallel Trends Implications*. McGill University. Montreal, QC. Retrieved from https://www.mcgill.ca/epi-biostat-occh/files/epi-biostat-occh/abilinski-announcement-11jan2021_0.pdf

Bouttell, J., Craig, P., Lewsey, J., Robinson, M., & Popham, F. (2018). Synthetic control methodology as a tool for evaluating population-level health interventions. *J Epidemiol Community Health, 72*(8), 673-678. doi:10.1136/jech-2017-210106

Box, G. E., Jenkins, G. M., & Reinsel, G. C. (2011). *Time Series Analysis: Forecasting and Control*: John Wiley & Sons.

Canadian Centre on Substance Abuse, & Canadian Community Epidemiology Network on Drug Use. (2016). *CCENDU Bulletin: The Availability of Take-Home Naloxone in Canada*. Retrieved from Ottawa, ON: https://www.ccsa.ca/sites/default/files/2019-05/CCSA-CCENDU-Take-Home-Naloxone-Canada-2016-en.pdf

Canadian Institute for Health Information. (2018). *Opioid-Related Harms in Canada, December 2018*. Retrieved from Ottawa, ON: https://www.cihi.ca/sites/default/files/document/opioid-related-harms-report-2018-en-web.pdf

Canadian Pharmacists Association. (2017). *Environmental Scan: Access to naloxone across Canada*. Retrieved from Ottawa, ON: https://www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-issues/Environmental%20Scan%20-%20Access%20to%20Naloxone%20Across%20Canada_Final.pdf

Castanho Silva, B., & DeWitt, M. (2020). SCtools: Extensions for Synthetic Controls Analysis. R package version 0.3.1.

Caulkins, J. P., Pardo, B., & Kilmer, B. (2019). Supervised consumption sites: a nuanced assessment of the causal evidence. *Addiction, 114*(12), 2109-2115. doi:https://doi.org/10.1111/add.14747

Collins, A. B., Boyd, J., Mayer, S., Fowler, A., Kennedy, M. C., Bluthenthal, R. N., . . . McNeil, R. (2019). Policing space in the overdose crisis: A rapid ethnographic study of the impact of law enforcement practices on the effectiveness of overdose prevention sites. *International Journal of Drug Policy, 73*, 199-207. doi:https://doi.org/10.1016/j.drugpo.2019.08.002

Degli Esposti, M., Spreckelsen, T., Gasparrini, A., Wiebe, D. J., Bonander, C., Yakubovich, A. R., & Humphreys, D. K. (2020). Can synthetic controls improve causal inference in interrupted time series evaluations of public health interventions? *Int J Epidemiol, 49*(6), 2010-2020. doi:10.1093/ije/dyaa152

Foreman-Mackey, A., Bayoumi, A. M., Miskovic, M., Kolla, G., & Strike, C. (2019). 'It's our safe sanctuary': Experiences of using an unsanctioned overdose prevention site in Toronto, Ontario. *International Journal of Drug Policy, 73*, 135-140. doi:https://doi.org/10.1016/j.drugpo.2019.09.019

Gogolishvili, D., & Wasdell, M. (2020). *Effectiveness of take-home naloxone programs and availability of naloxone nasal spray in different jurisdictions*. Retrieved from Toronto, ON: https://www.ohtn.on.ca/rapid-response-effectiveness-of-take-home-naloxone-programs-and-availability-of-naloxone-nasal-spray-in-different-jurisdictions/

Government of Canada. (2018, 03 August 2018). About the Good Samaritan Drug Overdose Act. Retrieved from https://www.canada.ca/en/health-canada/services/substance-use/problematic-prescription-drug-use/opioids/about-good-samaritan-drug-overdose-act.html

Government of Ontario. (2020). Ontario Demographic Quarterly: Highlights of first quarter 2020. Retrieved from https://www.ontario.ca/page/ontario-demographic-quarterly-highlights-first-quarter-2020

Hedlund, J. (2000). Risky business: safety regulations, risk compensation, and individual behavior. *Injury Prevention, 6*(2), 82-89. doi:10.1136/ip.6.2.82

Irvine, M. A., Kuo, M., Buxton, J. A., Balshaw, R., Otterstatter, M., Macdougall, L., . . . Gilbert, M. (2019). Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. *Addiction, 114*(9), 1602-1613. doi:https://doi.org/10.1111/add.14664

Izenberg, D., Iroanyah, N., & Thompson, S. (2018). Uninsured patients in Ontario: People get sicker, the system pays more. *Healthy Debate*. Retrieved from https://healthydebate.ca/2018/07/topic/uninsured-patients-ontario/

Kennedy, M. C., Hayashi, K., Milloy, M. J., Wood, E., & Kerr, T. (2019). Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study. *PLOS Medicine, 16*(11), e1002964. doi:10.1371/journal.pmed.1002964

Marshall BDL, Milloy MJ, Wood E, Montaner JS, & Kerr T. (2011). Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. *Lancet, 377*(9775), 1429-1437.

Ministry of Health and Long-Term Care. (2018). *Consumption and treatment services: Application guide*. Retrieved from Toronto, ON: https://health.gov.on.ca/en/pro/programs/opioids/docs/CTS_application_guide_en.pdf

NCHECR. (2007). *Sydney Medically Supervised Injecting Centre Evaluation Report No. 4: Evaluation of service operation and overdose-related events*. Retrieved from Sydney, NSW: https://kirby.unsw.edu.au/sites/default/files/kirby/report/EvalRep4SMSIC.pdf

Ontario Agency for Health Protection and Promotion (Public Health Ontario). (2020). *Interactive Opioid Tool*. Retrieved from Toronto, ON: https://www.publichealthontario.ca/en/data-and-analysis/substance-use/interactive-opioid-tool

Ontario Ministry of Health, & Ontario Ministry of Long-Term Care. (2018). Applications Now Open for Overdose Prevention Sites. Retrieved from https://www.health.gov.on.ca/en/news/bulletin/2018/hb_20180111.aspx

Panagiotoglou, D. (2022). Evaluating the population-level effects of overdose prevention sites and supervised consumption sites in British Columbia, Canada: Controlled interrupted time series. *PLoS One, 17*(3), e0265665. doi:10.1371/journal.pone.0265665

Pivot Legal Society. (2020). Canada's supervised consumption and overdose prevention sites. Retrieved from https://www.pivotlegal.org/scs_ops_map

Potier C, Laprévote V, Dubois-Arber F, Cottencin O, & Rolland B. (2014). Supervised injection services: what has been demonstrated? A systematic literature review. *Drug Alcohol Depend, 1*(145), 48-68.

Public Health Ontario. (2020). *COVID-19 Guidance: Consumption and Treatment Services (CTS) Sites*. Retrieved from Toronto, Ontario: https://www.oha.com/Bulletins/CTS%20COVID-19%20Guidance%20Document%20-%20March%2023%202020%20Shared.pdf

R Core Team. (2014). R: A language and environment for statistical computing. In. Vienna, Austria: R Foundation for Statistical Computing.

Russell, C., Imtiaz, S., Ali, F., Elton-Marshall, T., & Rehm, J. (2020). 'Small communities, large oversight': The impact of recent legislative changes concerning supervised consumption services on small communities in Ontario, Canada. *Int J Drug Policy, 82*, 102822. doi:10.1016/j.drugpo.2020.102822

Scheim, A. I., Bouck, Z., Tookey, P., Hopkins, S., Sniderman, R., McLean, E., . . . Werb, D. (2021). Supervised consumption service use and recent non-fatal overdose among people who inject drugs in Toronto, Canada. *International Journal of Drug Policy, 87*, 102993. doi:https://doi.org/10.1016/j.drugpo.2020.102993

Special Advisory Committee on the Epidemic of Opioid Overdoses. (2022). *Opioid- and Stimulant-related Harms in Canada*. Retrieved from Ottawa: Public Health Agency of Canada: https://health-infobase.canada.com/substance-related-harms/opioids-stimulants/

Statistics Canada. (2020). *Life tables, 2016/2018*. Retrieved from Ottawa: https://www150.statcan.gc.ca/n1/daily-quotidien/200128/dq200128a-eng.htm

Strike, C., & Watson, T. M. (2019). Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada. *International Journal of Drug Policy, 71*, 178-182. doi:https://doi.org/10.1016/j.drugpo.2019.02.005

Tam, T. (2018). Commentary - Building the evidence base for sustained public health response to the opioid epidemic in Canada. [Commentaire - Constituer un ensemble de données probantes au service d'une action soutenue en santé publique en réponse à la crise des opioïdes au Canada]. *Health promotion and chronic disease prevention in Canada : research, policy and practice, 38*(6), 221-222. doi:10.24095/hpcdp.38.6.01

The Evaluation of Overdose Prevention Sites Working Group, & Lori Wagar. (2018). *Evaluation of Overdose Prevention Sites: Campbell River, Courtenay, Cowichan Valley, and Port Alberni - FINAL REPORT*. Retrieved from Victoria, BC: https://www.islandhealth.ca/sites/default/files/2018-10/evaluation-OPS-report.pdf

VanderWeele, T. J., & Shpitser, I. (2011). A new criterion for confounder selection. *Biometrics, 67*(4), 1406-1413. doi:10.1111/j.1541-0420.2011.01619.x


ED Visit Rate Over Time
Treated
Synthetic Control
Counterfactual
ED Visits per 100,000 Population
0
2
4
6
8
10
-36
-30
-24
-18
-12
-6
0
6
12
Months Before or After Intervention


Hospitalization Rate Over Time
Treated
Synthetic Control
Counterfactual
Hospitalizations per 100,000 Population
0.0
0.5
1.0
1.5
2.0
-36
-30
-24
-18
-12
-6
0
6
12
Months Before or After Intervention


Death Rate Over Time
Treatment
Synthetic Control
Counterfactual
Deaths per 100,000 population
0.0
0.5
1.0
1.5
2.0
-36
-30
-24
-18
-12
-6
0
6
12
Months Before or After Intervention

Figure 1. Controlled interrupted time series plots of aggregate analyses

Table of Contents

Table 1. Overdose Prevention Site and Consumption and Treatment Services hours of operation and booths/spaces available (pg. 2)

Table 2. Naloxone kits dispensed by Public Health Units and community-based organizations (pg. 5)

Table 3. Crude and adjusted segmented regression output for treated/synthetic control unit pairs and aggregate analysis (pg. 6)

Figure 1. Controlled interrupted time-series of opioid-related ED visits plotted per treated public health unit – synthetic control pair, with counterfactual (pg. 9)

Figure 2. Controlled interrupted time-series of opioid-related hospitalizations plotted per treated public health unit – synthetic control pair, with counterfactual (pg. 10)

Figure 3. Controlled interrupted time-series of opioid-related mortalities plotted per treated public health unit – synthetic control pair, with counterfactual (pg. 11)

Supplement Data Sources (pg. 12)

Table 1. Overdose Prevention Site and Consumption and Treatment Services hours of operation and booths/spaces available

Site / Address	Hours	Booths	Date	Notes	Source
Toronto Public Health - The Works **277 Victoria St.** **Toronto**	M – S: 4pm – 10pm	3	Aug 21 2017	Closed Mar 18 – Apr 17 2020	[1-3]
	M – S: 10 am – 10pm	6	Nov 8 2017		[2, 4]
	M – S: 10 am – 10pm		Jul 12 2018		[5]
	Su: 11am – 5pm M – S: 10am – 10pm		Oct 14 2018		[3]
	Su: 11am – 5pm M – S: 10am – 10pm		May 24 2019		[6]
	Su: 11am – 6pm M – S: 1:30pm – 8pm	2	Apr 18 2020		[3, 4]
	Su: 11am – 5pm M – S: 10am – 10pm		May 11 2020		[7]
Fred Victor **145 Queen St. E** **Toronto**	Su – S: 6pm – 12am	3	Feb 21 2018	Assume change in hours/capacity began March 18 2020	[8]
	Su – S: 6pm – 12am		July 12 2018		[5]
	Su – S: 8:30am – 12am		May 24 2019		[6]
	Su – S: 8:30am – 11pm	2	Apr 6 2020		[9, 10]
	Su – S: 8:30am – 11pm		Aug 5 2020		[11]
Moss Park OPS **134 Sherbourne St.** **Toronto**	Su: 12pm – 6pm T – S: 12pm – 6pm	5	Aug 12 2017	Assume no change in hours but reduced capacity began with updated spring hours	[12-14]
	Su: 12pm – 6pm T – S: 12pm – 10pm		Jul 12 2018		[5, 13]
	Su: 12pm – 6pm T – S: 12pm – 10pm	3	Apr 18 2020		[4]
Parkdale Queen West CHC **168 Bathurst St.** **Toronto**	M, T, R: 10am – 6pm W: 1pm – 6pm F: 9am – 5pm	4	Mar 16 2018	Assume hours of operation match office hours at opening	[15, 16]
	M, W, R: 9:30 am – 8pm T: 1pm – 8pm F: 9:30am – 4:30pm		Jul 12 2018		[5]
	M, T, R: 9:30 am – 8pm W: 1pm – 8pm F: 9:30am – 4:30pm		May 24 2019		[6]
	M, T, R: 10am – 6pm W: 1pm – 6pm F: 9:30am – 4:30pm	2	Mar 18 2020		[4, 17, 18]
Parkdale Queen West CHC **1229 Queen St. W**	Su – S: 12pm – 12am	3	Aug 16 2018		[19]
	M, T, R: 12pm – 8pm W : 1pm – 8pm F: 12pm – 5pm		May 24 2019		[6]
	M, T, R: 10am – 6pm W: 1pm – 6pm F: 9:30am – 4:30pm	2	March 2020		[4, 17, 18]
	M, T, R: 10am – 8pm W: 1pm – 6pm F: 9am – 5pm		Dec 22 2020		[20]
Regent Park CHC **465 Dundas St. E** **Toronto**	M, W – F: 9:30am – 6:30 pm T: 12pm – 6:30pm	2	April 27 2018	Assume same hours as first listed for July 2018	[21]
	M, W – F: 9:30am – 6:30 pm T: 12pm – 6:30pm		July 12 2018		[5]
	M, W – F: 9am – 6:30pm T: 12pm – 6:30pm		May 24 2019		[6]
	M, W – F: 9:30am – 4:30pm T: 12pm – 4:30pm		Mar 2020		[17]
	M, W – F: 9:30am – 4pm T: 12pm – 6:30pm		May 1 2020		[22]
South Riverdale CHC **955 Queen St. E** **Toronto**	M, T, R: 9:30am – 8pm W, F: 9:30 am – 5pm	4	Jul 12 2018		[5]
	M, T, R: 9:30am – 8pm		May 24 2019		[6]

	W, F: 9:30 am – 5pm				
Street Health OPS **338 Dundas St. E** **Toronto**	M – F: 11am – 4pm	2	Jun 27 2018	Assume same hours as first listed for July 2018	[23, 24]
	M – F: 11 am – 4pm		Jul 12 2018		[5]
	M, W – F: 9:30am – 4pm T: 11am – 4pm		May 24 2019		[6]
St. Stephen's Community House OPS **260 Augusta St.** **Toronto**	M – F: 7:30am – 3:30pm	2	Apr 25 2018		[25, 26]
	Su: 8 am – 11:00am M – F: 7:30 am – 11:30am		Jul 12 2018		[5]
	Su – F: 8am – 2pm		May 24 2019		[6]
Urban Core **71 Rebecca St.** **Hamilton**	Su: 4pm – 10:30pm M, T, R, F: 10:30am – 10:30pm W: 12:30 – 10:30pm S: 4pm – 10:30pm	3	Jun 5 2018	Assume change in booths beginning March 2020	[27, 28]
	S, S: 4pm – 10:30pm M, T, R, F: 10:30am – 10:30pm W: 12:30 – 10:30pm	2	Mar 18 2020		
	Su – S: 4pm – 10:30pm		Nov 30 2020		[29]
Street Health Centre and HARS Integrated Health Hub **661 Montreal St.** **Kingston**	Su – S: 4pm – 10pm	4	Jul 29 2018		[30, 31]
	Su – S: 11am – 7pm		Apr 2020		[32]
OPS /Carepoint CTS **#30 – 186 King St.** **London**	Su, S: 11am – 4pm M – F: 10 am – 4pm	4	Feb 12 2018	Assume changes in booths beginning March 2020	[33-35]
	Su – S: 9:30am – 9pm		Aug 5 2019		[33]
	Su – S: 9:30am – 9pm	2	Mar 18 2020		[36]
Positive Living Niagara **105 Queenston St.** **Niagara**	Su – S: 9:30am – 8:30pm	4	Dec 3 2018	Assume changes in booths beginning March 2020	[37]
	Su – S: 9:30am – 8:30pm		Apr 13 202		[38]
Overdose Prevention Ottawa **307 St. Patrick St.** **Ottawa**	Su – S: 6pm – 9pm	28	Aug 25 2017	8 injection spaces, 20 inhalation spaces Last day: Nov 9 2017	[39]
Ottawa Public Health SIS **179 Clarence St.** **Ottawa**	Su – S: 9am – 9pm	2	Sep 26 2017	Assume cuts to services began Jan 1 2020	[40]
	Su – S: 9am – 9pm	3	Feb 6 2017		[40]
	M – F: 9am – 5pm	2	Nov 6 2019		[41]
Sandy Hill CHC **221 Nelson St.** **Ottawa**	Su – S: 8am – 8pm	5	Apr 17 2018	Assume changes in booths beginning March 18 2020	[42]
	Su – S: 8am – 8pm	3	May 17 2020		[43]
Inner City Health **230 Murray St.** **Ottawa**	24/7	8	Nov 1 2017	Assume additional booths added towards end of first year of operation (Aug 2018)	[44, 45]
	24/7	12	Jul 3 2019		[46]
	24/7	13	Nov 6 2019		[41]
	24/7	6	Mar 18 2020		[47]
	24/7	8	Nov 2020		[47]
Somerset West CHC OPS **55 Eccles St.** **Ottawa**	M – F: 9am – 4 pm	4	May 2 2018		[48, 49]
	Su – S: 8:30am – 7:30pm		Jun 2019		[50, 51]
Path 525 – NorWest Community Centre **525 Simpson St.**	M – F: 9am – 5pm	4	Nov 27 2018	Assume number of booths planned are number in operation	[52]
	M – S: 10am – 6pm		Mar 24 2020		[53, 54]
Guelph CHC **150 Duke St. W** **Guelph**	Su – S: 10am – 5pm	2	May 5 2018	Assume changes in hours beginning March 2020; No mention of fewer	[55, 56]
	Su – S: 9am – 4:30pm	4	Feb 22 2020		[57]
	M – F: 9am – 5pm		April 2020		[58]

				booths	
Sanguen Health Centre	Su – S: 9am – 9pm	2	Oct 15 2019		[59]
150 Duke St.	Su – S: 9am – 9pm	5	Oct 9 2020		[60]
Waterloo					

CHC = Community Health Centre; CTS = Consumption and Treatment Service; SIS = Safe injection site; OPS=Overdose Prevention Site; Days of the week: Su=Sunday, M=Monday, T=Tuesday, W=Wednesday, R=Thursday, F=Friday, S=Saturday;

Monthly booth hours per treated public health unit are: $y_{it} = \sum_{n=1}^{N}(b_{nt} \times h_{nt})$

where *y* is the total booth-hours per treated public health unit *i* at month *t*, *b* is the number of booths in operation at a specific site *n*, and *h* is the number of hours operated that month.

Table 2. Naloxone kits dispensed by Public Health Units and community-based organizations

PHU	2014	2015	2016	2017	2018	2019	2020	2021	Source
Algoma				355	590	737			[61-63]
Brant County				172	428	1365*	1282*	5726*	[64-66]
Chatham-Kent				92	381	342	429	46~	[67-69]
Hamilton			924	3402	6412	17705	16613	17046§	[70, 71]
Durham Region				458 →					[72]
Eastern Ontario				13 →					[72]
Grey-Bruce				437	1337			2434	[73, 74]
Haldimand-Norfolk				0	352				[72, 75]
Haliburton					297	802			[72, 76]
Halton Region				226 →		223	320	418	[72, 77]
Hastings Prince Edward County			39	166	326	890			[78, 79]
Kingston				456	1419				[80]
Lambton				508	700	2015			[72, 81, 82]
Leeds				408 →					[72]
London	40	98	168	848	2381	5289			[83]
Niagara				1482 →		4761	5885	7876	[72] [84]
North Bay				500	2000	4000			[85]
Northwestern				825	816				[86, 87]
Ottawa			115	1300	5500				[88-90]
Peel				366	1376				[91]
Peterborough				833					[72]
Porcupine				224	906	2656			[92, 93]
Renfrew				53	197	233			[94-96]
Simcoe Muskoka			462	1700	1620	2595			[71, 97, 98]
Sudbury				1235		10010	15438*	24822*	[72, 99, 100]
Thunder Bay	34	32	35	554	2022	4216	6846		[101]
Timiskaming				18 →					[72]
Toronto	← 2000			7717	42294	51577	67012		[1, 102-104]
Waterloo			677	4703	6782				[105, 106]
Guelph				581 →	1419				[72, 107]
Windson-Essex				1461 →	3059	5378			[72, 108]
York				560 →		2380			[72, 109]

*Monthly counts available
§Quarterly counts available
~Most recent avaliable
→ July 1 2017 – June 30 2018
←2011 – 2015, inclusive

Table 3. Crude and adjusted segmented regression output for treated/synthetic control unit pairs and aggregate analysis

	Emergency department visits per 100,000 population				Hospitalizations per 100,000 population				Deaths per 100,000 population			
	Crude (95% CI)	P-value	Adj.* (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value
Toronto												
Pre-intervention trend, synthetic control (β_1)	0.07 (0.03, 0.10)	0.0001	0.08 (0.00, 0.16)	0.0375	0.00 (0.00, 0.01)	0.1034	0.02 (0.00, 0.04)	0.1067	0.01 (0.00, 0.02)	0.1381	0.00 (-0.03, 0.03)	0.8854
Pre-intervention level difference, treated (β_2)	0.23(-0.81, 1.28)	0.6616	-1.70 (-5.97, 2.57)	0.4340	0.04 (-0.12, 0.20)	0.6450	0.07 (-0.10, 0.25)	0.4235	0.17 (-0.09, 0.43)	0.1985	0.48 (-0.87, 1.83)	0.4863
Pre-intervention trend difference, treated (β_3)	0.02 (-0.03, 0.07)	0.4472	0.00 (-0.08, 0.07)	0.9858	0.00 (-0.01, 0.01)	0.5576	0.00 (-0.01, 0.01)	0.7711	0.01 (-0.01, 0.02)	0.2705	0.01 (-0.01, 0.03)	0.2539
Pre-intervention level difference, synthetic control (β_4)	0.14 (-0.84, 1.12)	0.7731	0.28 (-0.78, 1.34)	0.6025	0.08 (-0.07, 0.23)	0.3162	0.06 (-0.11, 0.24)	0.4881	0.05 (-0.19, 0.30)	0.6737	0.20 (-0.05, 0.45)	0.1191
Post-intervention trend difference, synthetic control (β_5)	0.00 (-0.05, 0.04)	0.8690	-0.02 (-0.07, 0.04)	0.5650	-0.01 (-0.01, 0.00)	0.0227	-0.01 (-0.03, 0.00)	0.0639	0.01 (0.00, 0.02)	0.0880	0.02 (-0.01, 0.04)	0.1555
Post-intervention level difference, treated (β_6)	0.84 (-0.54, 2.23)	0.2331	1.58 (0.04, 3.12)	0.0438	-0.07 (-0.29, 0.14)	0.5115	0.13 (-0.13, 0.38)	0.3331	-0.22 (-0.57, 0.13)	0.2115	0.20 (-0.17, 0.57)	0.2848
Post-intervention trend difference, treated (β_7)	-0.05 (-0.11, 0.01)	0.1367	-0.02 (-0.09, 0.04)	0.4745	0.00 (-0.01, 0.01)	0.4801	0.00 (-0.01, 0.01)	0.5156	0.00 (-0.02, 0.01)	0.7928	0.01 (-0.01, 0.02)	0.3482
Booth-hours, per hundred (β_8)			-0.28 (-0.90, 0.35)	0.3877			-0.02 (-0.13, 0.08)	0.6308			**-0.17 (-0.32, -0.02)**	0.0259
Individuals dispensed opioid for pain, per hundred (β_9)			-0.13 (-0.39, 0.13)	0.3303			0.00 (-0.04, 0.05)	0.8628			-0.01 (-0.07, 0.05)	0.7770
Individuals on OAT, per hundred (β_{10})			-0.43 (-2.03, 1.18)	0.6036			-1.03 (-2.65, 0.59)	0.2121			0.42 (-1.07, 1.91)	0.5804
Naloxone kits dispensed, per hundred (β_{11})			-0.51 (-1.59, 0.56)	0.3505			-0.18 (-0.37, 0.01)	0.0573			**-0.34 (-0.61, -0.08)**	0.0113
Hamilton												
Pre-intervention trend, synthetic control (β_1)	0.15 (0.08, 0.21)	0.0000	0.04 (-0.15, 0.22)	0.6802	0.00 (-0.01, 0.02)	0.6690	0.01 (-0.03, 0.06)	0.5453	0.02 (0.00, 0.04)	0.0177	0.01 (-0.04, 0.06)	0.6947
Pre-intervention level difference, treated (β_2)	0.31 (-1.65, 2.27)	0.7555	2.94 (-2.62, 8.49)	0.2998	0.19 (-0.35, 0.72)	0.4938	0.12 (-1.26, 1.51)	0.8601	0.40 (-0.10, 0.91)	0.1177	0.82 (-3.06, 4.66)	0.6844
Pre-intervention trend difference, treated (β_3)	0.00 (-0.09, 0.10)	0.9469	0.02 (-0.08, 0.11)	0.7488	0.00 (-0.03, 0.02)	0.8184	0.00 (-0.03, 0.03)	0.9570	0.01 (-0.01, 0.04)	0.2362	0.02 (-0.01, 0.04)	0.2771
Pre-intervention level difference, synthetic control (β_4)	0.28 (-1.66, 2.22)	0.7770	0.68 (-1.41, 2.77)	0.5231	-0.27 (-0.80, 0.25)	0.3075	-0.19 (-0.77, 0.39)	0.5135	-0.12 (-0.62, 0.38)	0.6430	-0.13 (-0.70, 0.43)	0.6448
Post-intervention trend difference, synthetic control (β_5)	-0.09 (-0.19, 0.01)	0.0662	0.02 (-0.16, 0.20)	0.8288	0.00 (-0.02, 0.03)	0.7966	0.00 (-0.02, 0.03)	0.7751	0.05 (0.02, 0.07)	0.0003	0.05 (0.01, 0.09)	0.0164
Post-intervention level difference, treated (β_6)	1.31 (-1.44, 4.06)	0.3499	7.68 (-0.63, 16.00)	0.0700	0.00 (-0.74, 0.75)	0.9929	0.13 (-2.21, 2.46)	0.9163	-0.06 (-0.77, 0.65)	0.8697	**2.98 (0.79, 5.16)**	**0.0075**
Post-intervention trend difference, treated (β_7)	-0.05 (-0.18, 0.09)	0.4998	-0.20 (-0.40, 0.01)	0.0603	0.01 (-0.03, 0.05)	0.6476	0.00 (-0.08, 0.08)	0.9995	**-0.07 (-0.10, -0.03)**	**0.0002**	**-0.12 (-0.17, -0.06)**	**<0.0001**
Booth-hours, per hundred (β_8)			-3.60 (-8.25, 1.06)	0.1297			-0.06 (-1.41, 1.28)	0.9250			**-1.68 (-2.87, -0.48)**	0.0060
Individuals dispensed opioid for pain, per hundred (β_9)			0.12 (-0.25, 0.48)	0.5262			0.04 (-0.06, 0.15)	0.4270			0.00 (-0.10, 0.09)	0.9323
Individuals on OAT, per hundred (β_{10})			2.59 (-2.55, 7.74)	0.3237			-0.15 (-1.62, 1.33)	0.8467			0.13 (-1.05, 1.31)	0.8314
Naloxone kits dispensed, per hundred (β_{11})			0.86 (-0.11, 1.84)	0.0827			-0.06 (-0.35, 0.23)	0.6738			0.07 (-0.12, 0.27)	0.4566
Kingston												
Pre-intervention trend, synthetic control (β_1)	0.15 (0.07, 0.23)	0.0002	0.15 (-0.05, 0.35)	0.1405	0.02 (0.00, 0.05)	0.0713	0.08 (0.00, 0.16)	0.0427	0.01 (0.00, 0.03)	0.1407	-0.01 (-0.07, 0.04)	0.5804
Pre-intervention level difference, treated (β_2)	1.23 (-1.08, 3.54)	0.2964	1.42 (-6.06, 8.90)	0.7098	0.37 (-0.40, 1.15)	0.3462	-2.52 (-6.25, 1.21)	0.1847	0.10 (0.00, 0.03)	0.7204	0.85 (-0.39, 2.08)	0.1788
Pre-intervention trend difference, treated (β_3)	0.07 (-0.04, 0.18)	0.2292	0.12 (0.00, 0.25)	0.0510	0.02 (-0.02, 0.06)	0.2594	0.01 (-0.04, 0.05)	0.8403	0.00 (-0.02, 0.03)	0.8128	0.02 (-0.02, 0.05)	0.3146
Pre-intervention level difference, synthetic control (β_4)	-0.28 (-2.58, 2.03)	0.8141	0.11 (-2.81, 3.02)	0.9432	-0.73 (-1.51, 0.04)	0.0629	-1.16 (-2.05, -0.27)	0.0104	-0.09 (-1.04, 0.86)	0.7562	-0.09 (-0.69, 0.51)	0.7654
Post-intervention trend difference, synthetic control (β_5)	0.04 (-0.08, 0.15)	0.5192	0.04 (-0.11, 0.18)	0.6327	-0.02 (-0.05, 0.02)	0.4486	-0.05 (-0.10, 0.00)	0.0566	0.02 (0.00, 0.05)	0.0875	0.04 (0.00, 0.07)	0.0406
Post-intervention level difference, treated (β_6)	-1.51 (-4.77, 1.76)	0.3655	-6.03 (-16.05, 3.98)	0.2376	0.76 (-0.34, 1.85)	0.1757	2.22 (-1.08, 5.52)	0.1869	0.23 (-0.55, 1.01)	0.5606	-0.98 (-3.26, 1.30)	0.4000

Post-intervention trend difference, treated (β_7)	-0.13 (-0.29, 0.04)	0.1257	-0.19 (-0.40, 0.02)	0.0721	**-0.07 (-0.13, -0.02)**	0.0118	-0.04 (-0.11, 0.03)	0.2177	-0.03 (-0.07, 0.01)	0.1277	-0.05 (-0.10, 0.00)	0.0654
Booth-hours, per hundred (β_8)			1.41 (-1.46, 4.29)	0.3356			-0.39 (-1.36, 0.57)	0.4237			0.37 (-0.31, 1.05)	0.2821
Individuals dispensed opioid for pain, per hundred (β_9)			**0.62 (0.12, 1.11)**	**0.0144**			**0.16 (0.00, 0.32)**	**0.0449**			0.02 (-0.10, 0.14)	0.7855
Individuals on OAT, per hundred (β_{10})			0.19 (-5.91, 6.29)	0.9518			-1.86 (-3.95, 0.24)	0.0820			0.52 (-0.27, 1.30)	0.1979
Naloxone kits dispensed, per hundred (β_{11})			1.12 (-0.21, 2.46)	0.0997			0.37 (-0.07, 0.81)	0.1033			0.19 (-0.25, 0.64)	0.3972
London												
Pre-intervention trend, synthetic control (β_1)	0.10 (0.02, 0.18)	0.0120	0.23 (0.05, 0.41)	0.0114	0.00 (-0.02, 0.02)	0.8755	0.03 (-0.01, 0.06)	0.1078	0.01 (-0.01, 0.02)	0.2685	0.05 (0.01, 0.08)	0.0076
Pre-intervention level difference, treated (β_2)	0.78 (-1.57, 3.12)	0.5164	-1.25 (-7.23, 4.74)	0.6834	0.16 (-0.37, 0.69)	0.5634	1.12 (0.00, 2.24)	0.0492	0.15 (-0.25, 0.55)	0.4642	1.52 (0.41, 2.63)	0.0072
Pre-intervention trend difference, treated (β_3)	0.04 (-0.07, 0.15)	0.5191	-0.03 (-0.18, 0.13)	0.7339	0.00 (-0.02, 0.03)	0.7280	0.01 (-0.02, 0.03)	0.5730	0.00 (-0.01, 0.02)	0.6699	-0.01 (-0.03, 0.01)	0.4646
Pre-intervention level difference, synthetic control (β_4)	-0.64 (-2.90, 1.63)	0.5816	-0.62 (-2.87, 1.63)	0.5883	-0.47 (-0.98, 0.05)	0.0747	-0.25 (-0.77, 0.28)	0.3583	-0.12 (-0.51, 0.27)	0.5341	-0.05 (-0.45, 0.35)	0.8049
Post-intervention trend difference, synthetic control (β_5)	0.21 (0.10, 0.32)	0.0001	**0.23 (0.12, 0.35)**	0.0001	0.01 (-0.01, 0.04)	0.2402	0.01 (-0.02, 0.04)	0.5853	0.02 (0.00, 0.04)	0.0573	0.00 (-0.03, 0.03)	0.9849
Post-intervention level difference, treated (β_6)	0.61 (-2.60, 3.81)	0.7108	**5.34 (1.61, 9.08)**	0.0050	0.50 (-0.22, 1.23)	0.1755	**1.06 (0.18, 1.95)**	0.0186	-0.01 (-0.56, 0.54)	0.9719	0.51 (-0.15, 1.17)	0.1330
Post-intervention trend difference, treated (β_7)	-0.13 (-0.28, 0.02)	0.0949	**-0.19 (-0.37, -0.01)**	0.0413	**-0.04 (-0.07, 0.00)**	0.0271	**-0.06 (-0.11, -0.02)**	0.0107	0.01 (-0.02, 0.03)	0.5354	-0.02 (-0.06, 0.02)	0.3069
Booth-hours, per hundred (β_8)			**-2.97 (-4.45, -1.49)**	0.0001			-0.37 (-0.77, 0.02)	0.0659			**-0.45 (-0.76, -0.14)**	0.0041
Individuals dispensed opioid for pain, per hundred (β_9)			0.37 (-0.05, 0.79)	0.0832			0.08 (-0.01, 0.18)	0.0923			0.06 (-0.01, 0.13)	0.0890
Individuals on OAT, per hundred (β_{10})			-1.69 (-4.41, 1.03)	0.2238			-0.85 (-2.33, 0.63)	0.2614			**-1.28 (-2.49, -0.07)**	0.0389
Naloxone kits dispensed, per hundred (β_{11})			-0.22 (-0.99, 0.56)	0.5855			**-0.34 (-0.56, -0.12)**	0.0023			-0.11 (-0.28, 0.06)	0.1867

	Emergency department visits per 100,000 population				Hospitalizations per 100,000 population				Deaths per 100,000 population			
	Crude (95% CI)	P-value	Adj.* (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value
Niagara												
Pre-intervention trend, synthetic control (β_1)	0.17 (0.07, 0.27)	0.0008	0.16 (-0.08, 0.40)	0.2022	0.00 (-0.02, 0.02)	0.8813	0.00 (-0.05, 0.05)	0.9961	0.03 (0.01, 0.05)	0.0010	0.01 (-0.03, 0.05)	0.6682
Pre-intervention level difference, treated (β_2)	4.52 (1.49, 7.54)	0.0034	3.73 (0.76, 6.70)	0.0138	0.45 (-0.16, 1.07)	0.1506	0.09 (-0.70, 0.89)	0.8185	0.43 (-0.11, 0.97)	0.1198	0.52 (-0.10, 1.14)	0.0983
Pre-intervention trend difference, treated (β_3)	0.13 (-0.01, 0.27)	0.0698	0.13 (-0.01, 0.27)	0.0673	0.02 (-0.01, 0.05)	0.1480	0.03 (0.00, 0.06)	0.0648	0.01 (-0.02, 0.03)	0.6772	0.00 (-0.02, 0.03)	0.8667
Pre-intervention level difference, synthetic control (β_4)	0.31 (-2.84, 3.46)	0.8466	-0.20 (-3.51, 3.12)	0.9076	-0.84 (-1.48, -0.20)	0.0106	-0.65 (-1.36, 0.07)	0.0754	0.13 (-0.43, 0.70)	0.6462	0.00 (-0.64, 0.65)	0.9982
Post-intervention trend difference, synthetic control (β_5)	-0.12 (-0.30, 0.06)	0.1992	-0.08 (-0.30, 0.14)	0.4772	0.02 (-0.01, 0.06)	0.2387	0.03 (-0.02, 0.07)	0.2670	0.00 (-0.03, 0.03)	0.8787	0.02 (-0.02, 0.06)	0.4082
Post-intervention level difference, treated (β_6)	-2.65 (-7.10, 1.81)	0.2440	**25.88 (6.44, 45.33)**	0.0091	0.30 (-0.61, 1.21)	0.5241	2.92 (-1.32, 7.14)	0.1775	-0.67 (-1.47, 0.13)	0.0983	4.67 (0.99, 8.35)	0.0129
Post-intervention trend difference, treated (β_7)	-0.13 (-0.38, 0.12)	0.3130	**-0.49 (-0.82, -0.15)**	0.0044	-0.05 (-0.10, 0.00)	0.0508	**-0.08 (-0.16, -0.01)**	0.0219	0.03 (-0.01, 0.08)	0.1364	-0.03 (-0.09, 0.04)	0.3798
Booth-hours, per hundred (β_8)			**-9.70 (-16.08, 3.31)**	0.0029			-0.89 (-2.28, 0.50)	0.2111			**-1.78 (-2.99, -0.58)**	0.0037
Individuals dispensed opioid for pain, per hundred (β_9)			0.40 (-0.16, 0.97)	0.1583			0.07 (-0.05, 0.19)	0.2614			-0.07 (-0.17, 0.04)	0.2103
Individuals on OAT, per hundred (β_{10})			-2.35 (-9.09, 4.38)	0.4934			0.63 (-0.90, 2.17)	0.4205			0.23 (-1.06, 1.52)	0.7302
Naloxone kits dispensed, per hundred (β_{11})			**2.49 (0.98, 4.00)**	0.0013			0.02 (-0.33, 0.36)	0.9290			0.11 (-0.18, 0.39)	0.4581
Ottawa												
Pre-intervention trend, synthetic control (β_1)	0.05 (0.02, 0.08)	0.0011	0.03 (-0.03, 0.09)	0.3768	0.01 (0.00, 0.01)	0.079	0.00 (-0.02, 0.02)	0.6788	0.00 (0.00, 0.01)	0.3272	0.01 (-0.01, 0.03)	0.2387
Pre-intervention level difference, treated (β_2)	0.03 (-0.83, 0.89)	0.9450	0.30 (-2.86, 3.46)	0.8524	0.07 (-0.16, 0.29)	0.5515	0.31 (-0.53, 1.15)	0.4679	0.03 (-0.18, 0.25)	0.7589	-0.26 (-1.01, 0.49)	0.4997
Pre-intervention trend difference, treated (β_3)	0.00 (-0.04, 0.04)	0.9889	-0.01 (-0.04, 0.03)	0.7889	0.00 (-0.01, 0.01)	0.8868	0.00 (-0.01, 0.02)	0.8182	0.00 (-0.01, 0.01)	0.6302	0.00 (-0.01, 0.01)	0.8024
Pre-intervention level difference, synthetic control (β_4)	0.84 (0.03, 1.64)	0.0425	0.70 (-0.03, 1.42)	0.0590	-0.03 (-0.24, 0.18)	0.8132	-0.02 (-0.25, 0.22)	0.8926	0.04 (-0.16, 0.25)	0.6672	0.01 (-0.19, 0.22)	0.9060
Post-intervention trend difference, synthetic control (β_5)	-0.03 (-0.06, 0.01)	0.1357	-0.02 (-0.08, 0.04)	0.4980	-0.01 (-0.02, 0.00)	0.0417	-0.01 (-0.02, 0.01)	0.3411	0.01 (0.00, 0.02)	0.1311	0.00 (-0.01, 0.02)	0.8950
Post-intervention level difference, treated (β_6)	**-1.32 (-2.47, -0.18)**	0.0233	0.62 (-0.59, 1.84)	0.3155	-0.24 (-0.54, 0.05)	0.1087	-0.23 (-0.53, 0.12)	0.1911	-0.06 (-0.35, 0.23)	0.6831	0.27 (-0.06, 0.60)	0.1094
Post-intervention trend difference, treated (β_7)	**0.07 (0.02, 0.12)**	0.0057	**0.05 (0.00, 0.11)**	0.0381	0.00 (-0.01, 0.02)	0.7004	0.00 (-0.01, 0.02)	0.9773	0.00 (-0.01, 0.01)	0.8765	0.01 (-0.01, 0.02)	0.4505
Booth-hours, per hundred (β_8)			**-0.26 (-0.34, -0.17)**	**<0.0001**			0.00 (-0.03, 0.02)	0.7200			**-0.04 (-0.07, -0.02)**	0.0008
Individuals dispensed opioid for pain, per hundred (β_9)			-0.12 (-0.30, 0.07)	0.2203			0.04 (-0.01, 0.09)	0.1559			-0.01 (-0.06, 0.05)	0.8074
Individuals on OAT, per hundred (β_{10})			1.09 (-4.38, 6.56)	0.6967			0.24 (-0.68, 1.16)	0.6078			-0.60 (-2.02, 0.82)	0.4099
Naloxone kits dispensed, per hundred (β_{11})			**0.40 (0.03, 0.78)**	0.0354			0.05 (-0.06, 0.16)	0.3325			-0.03 (-0.13, 0.08)	0.6314
Thunder Bay												
Pre-intervention trend, synthetic control (β_1)	0.15 (0.07, 0.24)	0.0005	0.10 (-0.03, 0.23)	0.1237	0.01 (-0.02, 0.04)	0.3679	0.01 (-0.03, 0.06)	0.5316	0.03 (0.00, 0.06)	0.0716	0.05 (0.00, 0.10)	0.0306
Pre-intervention level difference, treated (β_2)	3.59 (1.00, 6.18)	0.0067	-1.44 (-15.19, 12.31)	0.8374	0.61 (-0.26, 1.47)	0.1689	1.77 (-2.68, 6.22)	0.4355	1.22 (0.30, 2.13)	0.0095	3.15 (-1.26, 7.55)	0.1613
Pre-intervention trend difference, treated (β_3)	0.12 (0.00, 0.24)	0.0556	0.10 (-0.04, 0.24)	0.1531	0.02 (-0.02, 0.06)	0.4362	0.02 (-0.03, 0.06)	0.4571	0.03 (-0.01, 0.08)	0.1346	0.04 (0.00, 0.09)	0.0676
Pre-intervention level difference, synthetic control (β_4)	-0.31 (-2.99, 2.37)	0.8210	-0.36 (-3.19, 2.46)	0.8005	-0.55 (-1.44, 0.35)	0.2307	-0.54 (-1.50, 0.42)	0.2690	-0.10 (-1.04, 0.85)	0.8431	-0.12 (-1.13, 0.88)	0.8104
Post-intervention trend difference, synthetic control (β_5)	0.31 (0.16, 0.46)	0.0000	0.28 (0.13, 0.43)	0.0002	0.00 (-0.05, 0.05)	0.8802	0.00 (-0.05, 0.05)	0.8938	0.04 (-0.02, 0.09)	0.1884	0.03 (-0.02, 0.08)	0.2482
Post-intervention level difference, treated (β_6)	-1.75 (-5.54, 2.03)	0.3640	-0.10 (-6.73, 6.53)	0.9758	-0.49 (-1.72, 0.81)	0.4825	-0.65 (-2.99, 1.69)	0.5855	-0.86 (-2.20, 0.48)	0.2087	1.26 (-1.13, 3.65)	0.3021

Post-intervention trend difference, treated (β_7)	**-0.36 (-0.57, -0.15)**	0.0007	**-0.35 (-0.60, -0.10)**	0.0054	-0.01 (-0.08, 0.06)	0.6805	-0.01 (-0.10, 0.07)	0.7742	0.00 (-0.08, 0.07)	0.9259	0.05 (-0.04, 0.13)	0.2837
Booth-hours, per hundred (β_8)			-0.43 (-1.89, 1.03)	0.5630			0.03 (-0.48, 0.54)	0.9065			**-0.55 (-1.08, -0.03)**	**0.0398**
Individuals dispensed opioid for pain, per hundred (β_9)			0.27 (-0.13, 0.68)	0.1805			0.02 (-0.13, 0.17)	0.7678			0.01 (-0.15, 0.17)	0.8994
Individuals on OAT, per hundred (β_{10})			0.52 (-0.95, 1.99)	0.4879			-0.14 (-0.62, 0.33)	0.5619			-0.21 (-0.69, 0.27)	0.3947
Naloxone kits dispensed, per hundred (β_{11})			**0.85 (0.05, 1.66)**	0.0378			0.14 (-0.19, 0.47)	0.4155			-0.15 (-0.45, 0.16)	0.3416
Guelph												
Pre-intervention trend, synthetic control (β_1)	0.07 (0.03, 0.12)	0.0016	0.09 (-0.02, 0.21)	0.1035	0.01 (-0.01, 0.03)	0.2880	0.00 (-0.05, 0.05)	0.9854	0.01 (0.00, 0.03)	0.0815	0.02 (-0.02, 0.06)	0.3150
Pre-intervention level difference, treated (β_2)	0.41 (-0.96, 1.77)	0.5579	-1.02 (-6.45, 4.42)	0.7140	-0.08 (-0.61, 0.45)	0.7752	-0.10 (-2.56, 2.37)	0.9395	-0.08 (-0.50, 0.35)	0.7263	-0.16 (-2.26, 1.94)	0.8794
Pre-intervention trend difference, treated (β_3)	0.01 (-0.06, 0.07)	0.8003	-0.01 (-0.11, 0.08)	0.8096	0.00 (-0.03, 0.02)	0.9755	0.00 (-0.04, 0.04)	0.9861	0.00 (-0.02, 0.02)	0.9159	0.00 (-0.03, 0.03)	0.8596
Pre-intervention level difference, synthetic control (β_4)	0.48 (-0.86, 1.83)	0.4812	0.36 (-1.01, 1.74)	0.6020	-0.18 (-0.70, 0.34)	0.4952	-0.19 (-0.75, 0.38)	0.5170	-0.03 (-0.45, 0.39)	0.8806	0.05 (-0.50, 0.60)	0.8598
Post-intervention trend difference, synthetic control (β_5)	-0.06 (-0.12, 0.01)	0.0992	-0.07 (-0.17, 0.03)	0.1802	-0.01 (-0.03, 0.02)	0.5010	-0.01 (-0.05, 0.02)	0.5221	0.01 (-0.01, 0.03)	0.4019	0.01 (-0.02, 0.04)	0.6366
Post-intervention level difference, treated (β_6)	1.38 (-0.52, 3.29)	0.1535	-1.13 (-3.87, 1.61)	0.4198	0.40 (-0.34, 1.14)	0.2890	0.07 (-1.06, 1.19)	0.9092	0.29 (-0.31, 0.88)	0.3491	0.04 (-0.96, 1.04)	0.9392
Post-intervention trend difference, treated (β_7)	-0.07 (-0.16, 0.03)	0.1655	-0.16 (-0.38, 0.06)	0.1519	-0.02 (-0.06, 0.01)	0.2232	-0.04 (-0.12, 0.04)	0.2926	-0.02 (-0.05, 0.01)	0.1789	-0.01 (-0.08, 0.05)	0.7275
Booth-hours, per hundred (β_8)			**2.39 (0.73, 4.04)**	0.0046			0.28 (-0.40, 0.95)	0.4194			0.17 (-0.36, 0.71)	0.5265
Individuals dispensed opioid for pain, per hundred (β_9)			0.01 (-0.29, 0.32)	0.9394			-0.07 (-0.20, 0.05)	0.2549			0.04 (-0.06, 0.14)	0.4112
Individuals on OAT, per hundred (β_{10})			-1.31 (-6.12, 3.50)	0.5923			0.02 (-2.03, 2.07)	0.9873			-0.09 (-1.73, 1.55)	0.9161
Naloxone kits dispensed, per hundred (β_{11})			0.18 (-0.74, 1.10)	0.7055			0.06 (-0.30, 0.42)	0.7386			-0.07 (-0.33, 0.19)	0.5955

	Emergency department visits per 100,000 population				Hospitalizations per 100,000 population				Deaths per 100,000 population			
	Crude (95% CI)	P-value	Adj.* (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value	Crude (95% CI)	P-value	Adj. (95% CI)	P-value
Waterloo												
Pre-intervention trend, synthetic control (β_1)	0.13 (0.07, 0.18)	0.0000	0.00 (-0.16, 0.16)	0.9817	0.00 (-0.01, 0.01)	0.8837	-0.05 (-0.08, -0.02)	0.0023	0.02 (0.00, 0.03)	0.0308	-0.01 (-0.05, 0.04)	0.7641
Pre-intervention level difference, treated (β_2)	-0.56 (-2.24, 1.11)	0.5111	9.39 (-3.57, 22.35)	0.1555	-0.26 (-0.66, 0.14)	0.1971	1.90 (-0.38, 4.17)	0.1027	-0.15 (-0.61, 0.30)	0.5053	0.52 (-1.90, 2.93)	0.6737
Pre-intervention trend difference, treated (β_3)	-0.04 (-0.12, 0.04)	0.2936	-0.01 (-0.10, 0.08)	0.8676	-0.01 (-0.03, 0.01)	0.1961	-0.02 (-0.04, 0.00)	0.0438	-0.02 (-0.04, 0.01)	0.1493	-0.01 (-0.04, 0.02)	0.4254
Pre-intervention level difference, synthetic control (β_4)	-1.52 (-3.49, 0.46)	0.1319	-0.72 (-2.83, 1.40)	0.5072	-0.41 (-0.88, 0.06)	0.0837	-0.44 (-0.92, 0.05)	0.0766	-0.37 (-0.90, 0.16)	0.1736	-0.21 (-0.82, 0.39)	0.4918
Post-intervention trend difference, synthetic control (β_5)	0.25 (0.09, 0.42)	0.0031	0.19 (0.01, 0.37)	0.0423	0.04 (0.00, 0.08)	0.0460	0.05 (0.01, 0.09)	0.0088	0.07 (0.02, 0.11)	0.0036	0.07 (0.01, 0.13)	0.0142
Post-intervention level difference, treated (β_6)	-0.38 (-3.17, 2.41)	0.7876	-1.20 (-4.09, 1.70)	0.4187	0.69 (0.03, 1.35)	0.0415	**0.73 (0.05, 1.54)**	**0.0359**	0.16 (-0.59, 0.92)	0.6696	0.03 (-0.81, 0.88)	0.9373
Post-intervention trend difference, treated (β_7)	-0.21 (-0.45, 0.02)	0.0775	-0.05 (-0.46, 0.36)	0.8119	-0.03 (-0.08, 0.03)	0.3645	0.05 (-0.05, 0.15)	0.2914	-0.01 (-0.08, 0.05)	0.6739	0.01 (-0.11, 0.13)	0.8911
Booth-hours, per hundred (β_8)			0.21 (-1.48, 1.91)	0.8065			-0.14 (-0.54, 0.27)	0.5092			-0.01 (-0.50, 0.48)	0.9687
Individuals dispensed opioid for pain, per hundred (β_9)			-0.09 (-0.53, 0.34)	0.6705			**-0.22 (-0.33, -0.10)**	**0.0002**			-0.02 (-0.15, 0.11)	0.7523
Individuals on OAT, per hundred (β_{10})			5.05 (-1.72, 11.82)	0.1437			**2.62 (0.02, 5.22)**	**0.0480**			0.64 (-1.52, 2.80)	0.5617
Naloxone kits dispensed, per hundred (β_{11})			0.77 (-0.16, 1.71)	0.1052			0.18 (-0.08, 0.45)	0.1758			0.20 (-0.11, 0.52)	0.2042
Aggregate												
Pre-intervention trend, synthetic control (β_1)	0.08 (0.06, 0.09)	<0.0001	0.18 (0.09, 0.26)	0.0001	0.00 (0.00, 0.00)	0.0190	0.02 (0.00, 0.04)	0.0830	0.01 (0.00, 0.01)	<0.0001	0.06 (0.03, 0.08)	<0.0001
Pre-intervention level difference, treated (β_2)	1.63 (1.21, 2.06)	<0.0001	3.01 (1.81, 4.20)	<0.0001	0.33 (0.22, 0.44)	<0.0001	1.22 (-0.37, 2.82)	0.1332	0.33 (0.23, 0.44)	<0.0001	1.45 (0.91, 1.99)	<0.0001
Pre-intervention trend difference, treated (β_3)	0.05 (0.03, 0.07)	<0.0001	0.02 (0.01, 0.04)	0.0101	0.00 (0.00, 0.01)	0.1387	0.01 (0.00, 0.02)	0.1106	0.01 (0.00, 0.01)	0.0015	0.01 (0.00, 0.01)	0.0090
Pre-intervention level difference, synthetic control (β_4)	0.59 (0.03, 1.15)	0.0395	0.08 (-0.41, 0.57)	0.7569	-0.06 (-0.21, 0.09)	0.4142	-0.09 (-0.25, 0.07)	0.2649	0.09 (-0.05, 0.23)	0.2032	0.01 (-0.13, 0.14)	0.9375
Post-intervention trend difference, synthetic control (β_5)	-0.04 (-0.09, 0.01)	0.0857	-0.15 (-0.22, -0.09)	<0.0001	-0.01 (-0.02, 0.00)	0.2137	-0.02 (-0.03, 0.00)	0.0621	0.00 (-0.01, 0.02)	0.6299	-0.03 (-0.05, -0.01)	0.0013
Post-intervention level difference, treated (β_6)	-0.33 (-1.12, 0.46)	0.4041	**-0.79 (-1.54, -0.04)**	0.0400	0.05 (-0.16, 0.26)	0.6173	0.03 (-0.22, 0.27)	0.8392	-0.10 (-0.30, 0.10)	0.3205	-0.17 (-0.38, 0.04)	0.1143
Post-intervention trend difference, treated (β_7)	-0.07 (-0.14, 0.00)	0.0517	**-0.15 (-0.21, -0.08)**	<0.0001	-0.02 (-0.03, 0.00)	0.0685	**-0.02 (-0.05, 0.00)**	0.0269	-0.01 (-0.02, 0.01)	0.3967	-0.01 (-0.03, 0.01)	0.4378
Booth-hours, per hundred (β_8)			0.19 (-0.02, 0.40)	0.0760			0.05 (-0.03, 0.13)	0.6638			0.05 (-0.01, 0.11)	0.0780
Individuals dispensed opioid for pain, per hundred (β_9)			0.04 (-0.19, 0.27)	0.7469			-1.21 (-3.00, 0.58)	0.2058			0.03 (-0.03, 0.10)	0.3187
Individuals on OAT, per hundred (β_{10})			**-9.05 (-14.16, -3.94)**	0.0005			-1.21 (-3.00, 0.58)	0.1861			**-3.35 (-4.89, -1.81)**	<0.0001
Naloxone kits dispensed, per hundred (β_{11})			0.73 (-0.31, 1.76)	0.1694			-0.05 (-0.39, 0.30)	0.7848			**-0.38 (-0.67, -0.08)**	0.0119

*Adjusted for seasonality using harmonic terms and with robust standard errors generated using Newey-West method, except for aggregate analysis which does not adjust for seasonality given multiple baseline approach


Toronto
Synthetic Control
Counterfactual
Hamilton
Synthetic Control
Counterfactual
Kingston
Synthetic Control
Counterfactual
London
Synthetic Control
Counterfactual
Niagara
Synthetic Control
Counterfactual
Ottawa
Synthetic Control
Counterfactual
Thunder Bay
Synthetic Control
Counterfactual
Guelph
Synthetic Control
Counterfactual
Waterloo
Synthetic Control
Counterfactual
ED Visit Rate per 100,000 pop.
Months Before/After Intervention

Figure 1. Controlled interrupted time-series of opioid-related ED visits plotted per treated public health unit – synthetic control pair, with counterfactual; Dark vertical dashed line = March 2020; Counterfactual represents the expected outcome rates were the intervention set to 0 in the regression models



Figure 2. Controlled interrupted time-series of hospitalizations plotted per treated public health unit – synthetic control pair, with counterfactuals; Dark vertical dashed line = March 2020; Counterfactual represents the expected outcome rates were the intervention set to 0 in the regression models



Figure 3. Controlled interrupted time-series of mortalities plotted per treated public health unit – synthetic control pair, with counterfactuals; Dark vertical dashed line = March 2020; Counterfactual represents the expected outcome rates were the intervention set to 0 in the regression models

SUPPLEMENT DATA SOURCES

1. Medical Officer of Health, *Toronto Overdose Action Plan: Status Report 2018*, in *Report for Action*. 2018, City of Toronto: Toronto, ON.
2. CBC News, *Toronto's first permanent supervised injection site opens downtown*, in *CBC News*. 2017: Toronto, ON.
3. Surveillance & Epidemiology. *Toronto Overdose Information System*. 2021 16 September 2021]; Available from: https://public.tableau.com/app/profile/tphseu/viz/TOISDashboard_Final/ParamedicResponse
4. Draaisma, M. and I. Lucs, *The Works superised injection site reopens with physical distancing measures in place*, in *CBC News*. 2020: Toronto, ON.
5. Toronto Drop-In Network, *Overdose Prevention Site, Supervised Injection Services and Safe Consumption Service Hours List*. 2018: Toronto, ON.
6. Harm Reduction TO. *Supervised Consumption Services: OPS, SIS/SCS, & CTS*. 24 May 2019 August 30 2019]; Available from: https://harmreductionto.ca/sis-ops-scs-cts.
7. Toronto Public Health. *@TOPublicHealth*. 2020 16 September 2021]; Available from: https://twitter.com/topublichealth/status/1259885006396284929.
8. CBC News, *Toronto opens new safe injection site at Fred Victor Centre*, in *CBC News*. 2018: Toronto, ON.
9. Toronto Central Health Line. *Queen and Jarvis Site - Supervised Consumption Service*. 2021 1 October 2021]; Available from: https://www.torontocentralhealthline.ca/displayservice.aspx?id=182489.
10. Fred Victor. *Fred Victor's response to the COVID-19 pandemic*. 2020 12 October 2021]; Available from: https://www.fredvictor.org/fred-victors-response-to-the-covid-19-pandemic/.
11. Pride Toronto, *Community Resources in Response to COVID-19*. 2020.
12. Mullin, M., *Citing overdose 'crisis' police to allow unsanctioned Toronto injection site*, in *CBC News*. 2017: Toronto, ON.
13. Contenta, S. *Toronto Star: Overdose prevention workers save thousands of lives, but who's saving theirs?* 2019 1 September 2021]; Available from: https://www.srchc.ca/news/tag/ops/.
14. CTVNews.ca Staff, *Unsanctioned pop-up safe-injection site opens in Toronto*, in *CTV News*. 2017: Toronto, ON.
15. News Staff, *Safe injection site opens in Parkdale*, in *CityNews*. 2018: Toronto, ON.
16. Parkdale Queen West Community Health Centre. *Hours, Location & Phone Numbers*. 2018 12 September 2021]; Available from: https://pqwchc.org/supervised-injection-service-open-house/
17. City of Toronto. *Supervised Consumption Services*. 2021 16 September 2021]; Available from: https://www.toronto.ca/community-people/health-wellness-care/health-programs-advice/supervised-injection-services/.
18. Parkdale Queen West Community Health Centre. *Supervised Consumption Services (SCS) - Queen West Site*. 2020 5 September 2021]; Available from: https://pqwchc.org/programs-services/harm-reduction/supervised-consumption-services-scs/.
19. Parkdale Queen West Community Health Centre, *Frequently Asked Questions (FAQ) about the Overdose Prevention Site at Parkdale*. 2018, Parkdale Queen West Community Health Centre: Toronto, ON.
20. Toronto Central Health Line. *Parkdale Queen West Community Health Centre - Parkdale Site*. 2021 1 October 2021]; Available from: https://www.torontocentralhealthline.ca/displayservice.aspx?id=167074.
21. Jones, R.P., *New temporary safe injection sites open in Kensington, Regent Park*, in *CBC News*. 2018: Toronto, ON.
22. Regent Park Community Health Centre, *OPS Pamphlet*, R.P.C.H. Centre, Editor. 2020: Toronto, ON.
23. Kolla, G., R. Penn, and C. Long, *Evaluation of the Overdose Prevention Sites at Street Health and St. Stephen's Community House*. 2019, Street Health and St. Stephen's Community House: Toronto, ON.
24. Street Health Community Health Centre, *Street Health Overdose Prevention Site*, S. Health, Editor. 2018.
25. Toronto Drop-In Network. *Evaluation of the Overdose Prevention Services at St. Stephen's Community House and Street Health*. 2020 16 September 2021]; Available from: https://www.tdin.ca/resource.php?id=671.
26. St. Stephen's Community House. *Temporary overdose prevention site at 260 Augusta Ave*. 2018; Available from: https://www.sschto.ca/About-Us/In-The-News/News/Overdose-Prevention-Site-at-260-Augusta-Ave.
27. City of Hamilton. *Consumption and Treatment Services (CTS)*. 2018 16 September 2021]; Available from: https://www.hamilton.ca/city-initiatives/strategies-actions/consumption-and-treatment-services#:~:text=June%205%2C%202018%20Urban%20Core,Centre%20and%20Shelter%20Health%20Network.
28. Hamilton Urban Core Community Health Centre. *Consumption & Treatment Service*. 2018 [cited 2021; Available from:

http://hucchc.com/health-and-wellness-programs/harm-reduction/.

29. Hamilton Public Library. *Overdose Prevention Site*. 2020 18 September 2021]; Available from: https://redbook.hpl.ca/node/14141.
30. Hurdle, L., *Consumption and Treatment Services - Street Health Centre*. 2019, City of Kingston: Kingston, ON.
31. Ferguson, E., *Ministry to set up overdose prevention site*, in *The Kingston Whig Standard*. 2018: Kingston, ON.
32. Kingston Frontenac Lennox and Addincton Public Health. *Consumption and Treatment Services*. 2020 16 September 2021]; Available from: https://www.kflaph.ca/en/healthy-living/consumption-and-treatment-services-site.aspx.
33. Middlesex-London Health Unit. *Temporary Overdose Prevention Site (TOPS)*. 2018 16 September 2021]; Available from: https://www.healthunit.com/temporary-overdose-prevention-site.
34. CBC News, *Take a tour of London's Temporary Overdose Prevention Site*, in *CBC News*. 2018: Toronto, ON.
35. Kitching, S., *Overdose Prevention Site to Open Monday*. 2018, Blackburn News: London, ON.
36. Lupton, A. *COVID-19 puts new focus on space constraints at London's drug-use site*. 2020 16 September 2021]; Available from: https://www.cbc.ca/news/canada/london/covid-19-puts-new-focus-on-space-constraints-at-london-s-drug-use-site-1.5590576.
37. Clementson, L. *St. Catharines home to first supervised consumption site in Niagara region*. 2019 16 September 2021]; Available from: https://www.cbc.ca/news/canada/hamilton/st-catharins-consumption-sit-1.4963875.
38. The Welland Tribune, *Positive living Niagara facing challenges during pandemic*, in *Niagara Falls Review*. 2020: Niagara Region.
39. Ottawa Prevention, *Overdose Prevention Ottawa Summary Report*. 2018: Ottawa, ON.
40. Raymond, T., *Ottawa Public Health to expand supervised consumption services at Clarence Street*, in *CTV News*. 2018: Ottawa, ON.
41. CBC News, *Injection site scaling back hours due to funding shortfall*, in *CBC News*. 2019: Ottawa, ON.
42. Crawford, B., *City's first permanent supervised injection site opens at Sandy Hill Community Health Centre*, in *Ottawa Citizen*. 2018: Ottawa, ON.
43. Jones, R.P., *Injection sites scales back physical distancing rules to prevent ODs*, in *CBC News*. 2020: Ottawa, ON.
44. DelVillano, S., et al., *At-a-glance - Supervised Injection Services: a community-based response to the opioid crisis in the City of Ottawa, Canada*. Health promotion and chronic disease prevention in Canada : research, policy and practice, 2019. **39**(3): p. 112-115.
45. Payne, E., *Province supports new Inner City Health supervised injection site*, in *Ottawa Citizen*. 2017: Ottawa, ON.
46. Fagan, L., *ByWard Market supervised injeciton trailer to get permanent home*, in *CBC News*. 2019: Ottawa, ON.
47. Reynolds, C., *Supervised injection sites across Canada hampered by COVID-19*, in *The Canadian Press*. 2021.
48. Whan, C., *New temporary overdose prevention site opens in Somerset West*, in *Global News*. 2018: Ottawa, ON.
49. Raymond, T., *Somerset West CHC launches new supervised drug consumption site*, in *CTV News*. 2018: Ottawa, ON.
50. Pivot Legal Society. *Canada's supervised consumption and overdose prevention sites*. 2020 23 April 2021]; Available from: https://www.pivotlegal.org/scs_ops_map.
51. Pivot Legal Society. *Canada's Supervised Consumption and Overdose Prevention Sites*. 2019 16 September 2021]; Available from: https://www.pivotlegal.org/scs_ops_map.
52. Diaczuk, D., *Overdose prevention site now open*, in *TBnewswatch*. 2018: Thunder Bay, ON.
53. NorWest Community Health Centres. *NorWest CHC is expanding its harm reduction services*. 24 March 2020 16 September 2021]; Available from: https://www.norwestchc.org/locations/thunder-bay/programs/path-525.
54. 211 Ontario North. *Norwest community health centres: Path 525*. 2020 16 September 2021]; Available from: https://211north.ca/record/65782603/.
55. Groleau, C., *Overdose prevention site in Guelph logs 430 visits since opening*, in *CBC News*. 2018: Kitchener-Waterloo, ON.
56. Wellington-Duffering-Guelph, P.H. *Where to get take-home naloxone kits*. 2018 16 September 2021]; Available from: https://www.wdgpublichealth.ca/your-health/opioids-and-naloxone/local-opioid-resources.
57. Armstrong, K., *Guelph safe injection site to double its capacity*, in *GuelphToday*. 2020: Guelph, ON.
58. Centre, G.C.H. *Reduced Health Services Hours*. 2020 16 September 2021]; Available from: https://guelphchc.ca/reduced-health-service-hours/.
59. CBC News, *Here's what Kitchener's consumption treatment site looks like*, in *CBC News*. 2019: Kitchener-Waterloo.
60. Senoran, H., *Permanent CTS site coming to downtown Kitchener one year after temporary site opened*, in *CTV News*. 2020: Kitchener, ON.
61. The Corporation of the City of Sault Ste. Marie, *Council Correspondence*. 2019, City of Sault Ste. Marie: Sault Ste. Maria, ON.
62. Kelly, B., *Overdose does not discriminate*, in *The Brantford Expositor*. 2019: Sault Ste. Marie, ON.
63. The Sault Star, *News briefs*, in *The Sault Star*. 2019: Sault Ste. Marie.
64. Brant County Health Unit, *Annual Report 2017*. 2017.
65. Brant County Board of Health, *Regular Agenda*, in *Opioid Surveillance*. 2018: Brant County, ON.

66. Brant County Health Unit. *Brant/Brantford Opioid Information System*. 2021 16 September 2021]; Available from: https://www.bchu.org/StatsAndReports/Pages/Opioid-Information.aspx.
67. Chatham - Kent Public Health, *Annual Report 2017*. 2017: Chatham, ON.
68. Municipality of Chatham-Kent, *Improvements for CK Public Health's Harm Reduction Program*, in *Community Human Services - Public Health Unit*. 2021: Chatham, ON.
69. Chatham - Kent Public Health, *Opioid Surveillance Summary*. 2021.
70. City of Hamilton. *Hamilton Opioid Information System - Naloxone*. 2021 1 October 2021]; Available from: https://www.hamilton.ca/public-health/reporting/hamilton-opioid-information-system-naloxone.
71. Paddon, N., *Public health handing out more naloxone kits*, in *The Hamilton Spectator*. 2018: Hamilton, ON.
72. Tadrous, M., et al., *Naloxone Distribution Across Ontario*. 2019, Ontario Drug Policy Research Network: Toronto, ON.
73. Public Health Grey Bruce, *Grey Bruce Opioid Response Plan*. 2020: Grey Bruce, ON.
74. Public Health Grey Bruce, *Opioid Situation Report #1*. 2021: Grey Bruce, ON.
75. Health and Social Services Haldimand and Norfolk, *Health Unit Opioid Management Plan*. 2018, Haldimand Norfolk Health and Social Services: Haldimand, ON.
76. Haliburton, K., Pine Ridge District Health Unit, *2019 Annual Report: Strong Roots in our Communities*. 2020: Ontario.
77. Halton Region. *Opioid Reporting*. 2021 September 2021 1 October 2021]; Available from: https://www.halton.ca/For-Residents/Public-Health/Health-Statistics/Opioid-Reporting.
78. Hastings Prince Edward County Public Health, *The impact of opioids and other drugs in Hastings and Prince Edward Counties*. 2019, Hastings Prince Edward Public Health: Belleville, ON.
79. Hastings Prince Edward County Public Health, *2019 Annual Report*. 2021, Hastings Prince Edward Public Health: Belleville, ON.
80. Kingston Community Health Centres, *Annual Report 2017/18 Moving Upstream: Addressing the Social Determinants of Health*. 2019: Kingston, ON.
81. Lambton Public Health, *2018 Annual Report*. 2019: Lambton, ON.
82. Ontario Association of Fire Chiefs. *Analysis: Deep in the opioid crisis in Southwestern Ontario*. 2020; Available from: https://www.oafc.on.ca/article/analysis-deep-opioid-crisis-southwestern-ontario.
83. Middlesex-London Health Unit. *Opioids - What is the situation?* 2021 16 September 2021]; Available from: https://www.healthunit.com/opioids-middlesex-london#naloxone.
84. Niagara Region. *Naloxone use and distribution in Niagara (2019 - 2021)*. 2021 1 November 2021]; Available from: https://www.niagararegion.ca/living/health_wellness/alc-sub-abuse/drugs/opioids.aspx#topic5.
85. CBC News, *Naloxone use on the rise in Thunder Bay, health unit says*, in *CBC News*. 2019: Thunder Bay, ON.
86. Northwestern Health Unit, *2017 Public Health Report Card*. 2020, Northwestern Public Health.
87. Northwestern Health Unit, *Moving Forward: 2018 Public Health Report Card*. 2020, Northwestern Public Health.
88. Ottawa Board of Health, *Subject: Next steps in harm reduction and overdose prevention*. 2019, Ottawa Public Health: Ottawa, ON.
89. Ottawa Public Health, *2017 Annual Report*. 2018, Ottawa Public Health: Ottawa, ON.
90. Ottawa Public Health, *Subject: Ottawa overdose prevention and response task force: Update*. 2017, Ottawa Public Health: Ottawa, ON.
91. Region of Peel, *Peel Opioid Strategy: A local response*. 2019.
92. Porcupine health unit, *2017 Annual Report*. 2018.
93. Porcupine health unit, *Medical officer of health report to the board of health*. 2020, Porcupine Public Health.
94. Renfrew County and District Health Unit, *2017 Annual Report*. 2018.
95. Renfrew County and District Health Unit, *2018 Annual Report*. 2019.
96. Renfrew County and District Health Unit, *2019 Annual Report*. 2020.
97. Simcoe Muskoka District Health Unit, *2018 Status Update*, in *Simcoe Muskoka Opioid Strategy*. 2019.
98. Simcoe Muskoka District Health Unit, *Simcoe Muskoka Opioid Strategy Scorecard*. 2020.
99. Public Health Sudbury District, *A study to explore the need for and feasibility of implementing supervised consumption services in the City of Greater Sudbury*. 2021, Public Health Sudbury District.
100. Public Health Sudbury District. *Naloxone Distribution*. 2021 11 November 2021]; Available from: https://www.phsd.ca/health-topics-programs/alcohol-drugs/community-drug-strategy/research/opioid-surveillance/naloxone/.
101. Thunder Bay District Health Unit. *Opioid Information System*. 2021 2 November 2021]; Available from: https://www.phsd.ca/health-topics-programs/alcohol-drugs/community-drug-strategy/research/opioid-surveillance/naloxone/.
102. Medical Officer of Health, *Toronto Overdose Action Plan: Status Report 2019*, in *Report for Action*. 2019, City of Toronto: Toronto, ON.

103. Medical Officer of Health, *Toronto Overdose Action Plan: Status Report 2020*, in *Report for Action*. 2020, City of Toronto: Toronto, ON.
104. Medical Officer of Health, *Toronto Overdose Action Plan: Status Report 2021*, in *Report for Action*. 2021, City of Toronto: Toronto, ON.
105. Region of Waterloo, *Waterloo Region Supervised Injection Services Feasibility Study*. 2018: Waterloo, ON.
106. Regional Municipality of Waterloo, *Harm Reduction Planning, Programs and Services Update*. 2019, Region of Waterloo: Waterloo, ON.
107. Wellington-Dufferin-Guelph, P.H., *Naloxone Distribution Program*. 2019.
108. Windsor-Essex County Health Unit. *Opioid Overdose Statistics*. 2021 1 November 2021]; Available from: https://www.wechu.org/reports/opioid-overdose-statistics.
109. Regional Municipality of York, *York Region Public Health's Opioid Action Plan*. 2019.



Figure 1. Controlled interrupted time series plots of aggregate analyses